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Abstract 
Within a backup program for the clinical investigational agent pretomanid (PA-824), scaffold 
hopping from delamanid inspired the discovery of a novel class of potent antitubercular 
agents that unexpectedly possessed notable utility against the kinetoplastid disease visceral 
leishmaniasis (VL). Following the identification of delamanid analogue DNDI-VL-2098 as a 
VL preclinical candidate, this structurally related 7-substituted 2-nitro-5,6-
dihydroimidazo[2,1-b][1,3]oxazine class was further explored, seeking efficacious backup 
compounds with improved solubility and safety. Commencing with a biphenyl lead, 
bioisosteres formed by replacing one phenyl by pyridine or pyrimidine showed improved 
solubility and potency, whereas more hydrophilic side chains reduced VL activity. In a 
Leishmania donovani mouse model, two racemic phenylpyridines (71 and 93) were superior, 
with the former providing >99% inhibition at 12.5 mg/kg (b.i.d., orally) in the Leishmania 
infantum hamster model. Overall, the 7R enantiomer of 71 (79) displayed more optimal 
efficacy, pharmacokinetics and safety, leading to its selection as the preferred development 
candidate.  
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INTRODUCTION 
The neglected tropical disease visceral leishmaniasis (VL) is the second deadliest parasitic 
disorder (after malaria), being most prevalent in Brazil, Sudan, Ethiopia, and the Indian 
subcontinent, with an estimated 350 million people at risk of infection.1 Transmitted by sand 
flies, the disease first manifests as an irregular fever, anaemia, leukopenia, and 
hepatosplenomegaly, and is usually fatal within 2 years if left untreated.2 About 300,000 new 
cases arise annually, almost half in children, and at least 35 countries have reported the 
occurrence of HIV coinfection (with up to 34% incidence), which gives a significantly higher 
mortality rate.3,4 Unfortunately, none of the existing VL drugs (antimonials, paromomycin, 
liposomal amphotericin B, or miltefosine 1; see Figure 1) is universally effective, nor free 
from further drawbacks, such as parenteral administration (for all except 1), toxicity, high 
cost, and emerging resistance.5 Furthermore, there is no available vaccine, despite renewed 
efforts.6 Clinical investigation of the orally active aminoquinoline sitamaquine (2) has been 
abandoned due to its toxicity and less satisfactory efficacy,7 and new phase II trials of the 
repositioned oral agent fexinidazole (3)8 for VL have also been interrupted due to patient 
relapses.9 With no other candidates under clinical evaluation at present, there is a desperate 
need for the development of more effective, safe and affordable oral remedies for VL. 
We have recently reported that phenotypic screening by the Drugs for Neglected Diseases 
initiative (DNDi) of some nitroimidazole derivatives arising from our early studies with the 
TB Alliance unexpectedly led to the identification of DNDI-VL-2098 (4) as a preclinical 
candidate for VL.10,11 Our opening assignment with TB Alliance had been to prepare and 
evaluate novel nitroheterobicyclic analogues of the tuberculosis (TB) drugs delamanid (5) 
and pretomanid (PA-824, 6),12,13 seeking a possible third active scaffold for the construction 
of a backup series. However, amongst the fused 5/6 ring systems examined, only the 
metabolically labile 2-nitroimidazothiazines retained significant antitubercular potency,14 
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returning our attention to the original oxazine class where we uncovered heterobiaryl 
derivatives of 6 with better efficacy (e.g., TBA-354, 7).15,16 One important consideration in 
the design of a superior second-generation TB candidate was the potential for cleavage of the 
aromatic side chain via oxidative metabolism of the 6-oxymethylene linker; therefore, several 
alternative linker and steric protection strategies were explored, albeit, with limited 
success.17-19 A final, more innovative way to address this issue was to invoke a scaffold 
hopping approach,20 by relocating aromatic side chains from the 6-position to the 7-position 
of the 2-nitroimidazooxazine core, with attachment via the same inverted linker (CH2OR) 
that was present in 6-nitroimidazooxazole 5. This was equivalent to a one carbon expansion 
of the oxazole ring between C-2 and C-3 (Figure 2). The rationale for this design concept 
stemmed from initial evidence21 that delamanid (5) was highly stable towards metabolism, as 
well as from a report22 that 7-methyl derivatives of 6 retained excellent antitubercular 
potency, suggesting that such an approach merited investigation. 
Serendipitously, we soon discovered23 that this novel “7-substituted oxazine” class not only 
showed considerable promise for TB (as later confirmed by others24,25), it also displayed 
potent antileishmanial activity, comparable to the 6-nitroimidazooxazoles in early screening 
assays. Therefore, following the success with 4, this new series was similarly repositioned for 
VL as part of an extensive backup program, run in collaboration with DNDi. In this paper, we 
first highlight some critical VL hit to lead assessments on the original subset of compounds 
that had been prepared for TB. We then detail the findings of our lead optimisation study 
directed at developing backups to 4 having an improved physicochemical/pharmacological 
profile and better safety, which culminated in the selection of a new preclinical candidate for 
VL. Finally, in light of these encouraging results and the excellent activities of this novel 7-
substituted 2-nitroimidazooxazine class against both TB and Chagas disease, we point to 
related analogues that might be worthy of further assessment for the latter applications. 
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CHEMISTRY 
In order to rapidly access some initial examples, the racemic 7-H and 7-methyl alcohol 
intermediates, 13 and 20, were first sought (Scheme 1A). These could be obtained in very 
good overall yield (62-79%) via similar 5 step reaction sequences, starting with base 
catalysed alkylation of 2-bromo-4-nitroimidazole (8) using 4-bromobut-1-ene or 4-iodo-2-
methylbut-1-ene26 (15). Dihydroxylation of the resulting alkene (OsO4/NMO), selective TIPS 
protection of the primary hydroxyl group, sodium hydride-induced ring closure, and acid-
catalysed desilylation27 completed the synthesis of both alcohols, although in the case of 20, 
the final two steps required gentle warming. The benzyl ether targets 14, 21-23, 25, and 27-
29 were then formed by standard alkylation and Suzuki coupling methodology (Scheme 
1A/B). Next, the two enantiomers of early TB lead 29 (34 and 38) were also generated via 
preparative chiral HPLC separation of the 7R and 7S forms of acetate derivative 30, followed 
by hydrolysis to the chiral alcohols (32 and 36), and elaboration as before (Scheme 1C). 
Here, the absolute configurations of 34 and 38 were subsequently established through an 
independent chiral synthesis of the 7R enantiomer (see the Supporting Information), 
involving alkylation of 8 with the iodide derived from 2-[(2R)-2-methyl-1,4-
dioxaspiro[4.5]decan-2-yl]ethan-1-ol.28 
Mitsunobu coupling of alcohol 13 with appropriate phenols (Scheme 2A) successfully led 
to the 7-H phenyl ethers 39 and 45, together with the 4-iodo analogue 48; the latter enabled 
biphenyl derivatives 49 and 53, following Suzuki couplings. However, because Mitsunobu 
reactions were expected to be more problematic for the sterically hindered 7-methyl alcohol 
20,29 a different approach was employed to prepare compounds 44 and 47 (Scheme 2B). 
Commencing with 2-chloro-4-nitroimidazole (40), alkylation with iodide 1526 and buffered 
reaction of alkene 41 with m-CPBA provided epoxide 42 in high yield (80%). Ring opening 
of 42 with phenols (K2CO3, MEK, 82 °C) then gave alcohol intermediates that could be ring 
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closed to 7-substituted oxazines, as above. An attempt to combine the last two steps in one 
pot30 (by exposing 42 to 1.2 equivs of NaH and 4-(trifluoromethoxy)phenol in DMF at 75-86 
°C) led to markedly inferior results (27% 44, with 30% 43); equally, ring opening of 42 with 
4-iodophenol in DMF (K2CO3, 83 °C, 8 h) also gave a lower yield of 50 (60%) due to partial 
displacement of the 2-chlorine. Suzuki couplings on the ring-closed iodide 51 readily 
furnished biphenyl derivatives 52 and 54; terminal fluoropyridines 55 and 56 were similarly 
obtained from 48 and 51 through the use of a weaker base (KHCO3). 
The assembly of various biaryl side chains featuring a proximal 2-pyridine ring was 
typically quite straightforward (Scheme 2C). Bromo-2-pyridinyl ethers (58, 60, 98, and 100) 
were easily formed17 via sodium hydride-catalysed SNAr reactions of alcohols 13 and 20 with 
the fluoropyridines 57 and 97, and Suzuki couplings then supplied the phenylpyridine or 
bipyridine targets in generally high yields (62-98%). Nevertheless, it proved very challenging 
to prepare analogues 105 and 106 having a 2-pyridine terminal ring. One pot treatment of 
bromides 58 and 60 with bis(pinacolato)diboron (to generate the boronate ester), followed by 
in situ Suzuki coupling31 with 2-bromo-5-fluoropyridine, gave 105 and 106 in poor yields (8-
15%). However, a copper(I)-facilitated Suzuki approach,32 designed to mitigate facile 
protodeboronation of the required 2-pyridyl boronate, was not any better (15% yield of 106). 
For more efficient synthesis of 7-H biaryl analogues having a proximal 3-pyridine ring, an 
epoxide-opening strategy (Scheme 3A) was preferred over the Mitsunobu route described 
above. Epoxide 67 was obtained in 72% optimised yield from 2-chloro-4-nitroimidazole (40), 
via alkene 66; in this case, the slow epoxidation step was best achieved under non-buffered 
conditions at higher concentration (with initial cooling). Ring opening of 67 with 6-
bromopyridin-3-ol (68) (K2CO3, MEK, 81-82 °C) gave mainly alcohol 69 (51% using 2 equiv 
for 35 h, or 57% from 4 equiv and 14 h), together with small amounts of the oxazine 70 (6-
12%). Ring closure of purified 69 (NaH, DMF, 0-20 °C) then gave additional 70 in excellent 
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yield (91%). Comparable results were obtained for scale-up of 39 from 67 (62%), as well as 
for reaction of epoxide 42 with pyridinol 68 and ring closure, leading to oxazine 89 (Scheme 
3D). As expected, bromides 70 and 89 both proved to be excellent substrates for Suzuki 
couplings to access the remaining racemic phenylpyridine and bipyridine targets. 
By alkylating 2-chloro-4-nitroimidazole (40) with (4R)-4-(2-iodoethyl)-2,2-dimethyl-1,3-
dioxolane33 (72) (or its optical isomer, 8033), it was possible to transform the above racemic 
route into a viable chiral synthesis for delivery of both enantiomers of two advanced leads, 71 
and 93 (Scheme 3B/C). The two chiral acetal products 73 and 81 were readily converted into 
the R and S enantiomers of epoxide 67 (76 and 84) by successive hydrolysis (to diols 74 and 
82), tosylation at the primary hydroxyl, and internal substitution to form the oxirane ring 
(DBU). These chiral epoxides were then elaborated to the final products by reaction with 68, 
ring closure, and Suzuki coupling, as previously described. 
The preparation of biaryl congeners 123, 126, 129, 131-133, and 139 in which the first ring 
was pyridazine, pyrazine, or pyrimidine followed similar procedures to those developed for 
the pyridine analogues. Thus, sodium hydride-induced SNAr reactions of alcohols 13 and 20 
with haloheterocycles 121, 124, and 127 readily provided the bromoheteroaryl ether 
intermediates needed for final step Suzuki couplings (Scheme 4A). However, the remaining 
arylpyrimidine target (139) required prior assembly of the biaryl side chain. Initial protection 
of 2-chloropyrimidin-5-ol (134) as an ethoxymethyl ether derivative (135), followed by 
Suzuki coupling and acidic deprotection supplied arylpyrimidinol 137 in excellent yield (83% 
from 134; Scheme 4B). Reaction of 137 with epoxide 67 produced a 5:2 mixture of the 
alcohol 138 and the ring closed oxazine (139); treatment of 138 with sodium hydride then 
completed this synthesis. 
Scheme 5 outlines the methods used to obtain compounds 142, 144, 147, 149, 152, 154, 
157, 159-161, 170, and 178, whose side chains contained either piperazine or piperidine 
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linked to an aryl group. Ring opening of epoxides 67 and 42 with the known or commercial 
amines 140, 145, 150,34 and 155 easily generated the expected β-amino alcohols in high yield 
(Scheme 5A/B). These alcohols could be ring closed to the final products with sodium 
hydride upon mild heating; albeit, yields for the 7-methyl analogues were generally 
significantly lower, in part, due to greater purification difficulties. Chloroformylation of 
alcohols 13 and 20 (triphosgene/Et3N) and in situ reaction with arylpiperazine 140 also led to 
the O-carbamates 160 and 161 in only modest yield (33-35%; Scheme 5C) on account of 
similar purification issues; the isolation of alkyl chloride and diethyl carbamate derivatives 
under the same reaction conditions has been reported recently.35 Lastly, synthesis of the two 
O-linked arylpiperidines, 170 and 178, was eventually achieved in each case via a lengthy 7 
step route (Scheme 5D), after the failure of a more direct plan (ring opening of epoxide 67 
with piperidinol 16336 in the presence of erbium triflate37). Here, piperidinol 16336 was first 
sourced in three steps, by Buchwald amination of 1-bromo-4-fluorobenzene with 1,4-dioxa-8-
azaspiro[4.5]decane,38 ketal hydrolysis, and reduction (NaBH4). Reaction of epoxides 162
39 
and 17139 with 163 (NaH, DMF, 70 °C) and TBS protection of the liberated hydroxyls 
provided the desired ethers 165 and 173 in good yield (47-68% overall). Successive benzyl 
removal (via hydrogenolysis), iodination, and alkylation of 2-chloro-4-nitroimidazole (40) 
then gave the TBS-protected adducts, 168 and 176, which were readily desilylated (TBAF) 
and ring closed to furnish the final targets.  
RESULTS AND DISCUSSION 
The structures and in vitro antiparasitic and antitubercular potencies of 75 novel 7-substituted 
2-nitroimidazooxazine derivatives prepared in two collaborative projects are provided in 
Tables 1 and 2. While compounds 14, 21-23, 25, 27-29, 34, 38, 39, 44, 45, 47, 49, and 52-54 
were initially designed and evaluated for TB, for clarity purposes, we will focus the 
discussion first on the more recent VL work with DNDi. Here, new synthesis was directed at 
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the optimisation of solubility, efficacy, and safety, primarily through the incorporation of 
heterocycles to reduce compound lipophilicity11 (estimated by CLogP data derived from 
ACD LogP/LogD software, version 12.0; Advanced Chemistry Development Inc., Toronto, 
Canada). Kinetic aqueous solubility measurements were conducted on dry powder forms of 
particular examples that were being considered for further evaluation. Target compounds 
were initially screened only once against Leishmania donovani (L. don) using a mouse 
macrophage-based luciferase assay conducted at the Central Drug Research Institute (CDRI, 
India).10 Nevertheless, in order to gain a clearer understanding of the SAR (in view of some 
unexpected in vivo outcomes), the entire set was finally re-evaluated at the University of 
Antwerp (LMPH) in replicate assays against three protozoan parasites: L. infantum (L. inf), T. 
cruzi, and T. brucei.40 Assessments of cytotoxicity were concurrently conducted on both 
human lung fibroblasts (MRC-5 cells; the host for T. cruzi) and primary peritoneal mouse 
macrophages (the host for L. inf), which revealed that the compounds were generally 
nontoxic (MRC-5 IC50s >55 µM except for 117: IC50 35 µM), as confirmed for TB (VERO 
assay41 IC50s >128 µM for 71 of 72 compounds). 
1. Early hit to lead assessments for VL  
Through an agreement between TB Alliance and DNDi, 58 nitroimidazole derivatives were 
screened against L. don at the Swiss Tropical Institute. All five 7-substituted oxazines 
(including 22, 23, and 28) demonstrated excellent potencies in the in vitro mouse macrophage 
assay (IC50s 0.065-0.17 µM, similar to racemic 4), prompting the inclusion of 28 alongside 
rac-4 (and another oxazole11) in a proof-of-concept in vivo assessment at the London School 
of Hygiene and Tropical Medicine (LSHTM). However, the level of activity observed for 28 
in this L. don mouse model (49% inhibition at 50 mg/kg, dosing po daily for 5 d; Table 3) 
was not notable in comparison to the results for rac-4 (99% at 6.25 mg/kg),11 suggesting that 
further optimisation of the side chain would be necessary. Indeed, while 28 showed good 
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stability on exposure to mouse liver microsomes (MLM: 75% remaining after 1 h, Table 3) 
and gave a mouse pharmacokinetic (PK) profile comparable to rac-4 (Table 4 and Supporting 
Information, Figures S1 and S2), it was very hydrophobic (CLogP 5.14) and displayed poor 
solubility (~58 ng/mL at pH 7, Table 3; 62-fold lower than for rac-411). Such compounds 
typically exhibit high levels of plasma protein binding (PPB), which can limit efficacy.42 We 
have also observed that increased linker flexibility can be detrimental to in vivo activity.17,43 
While these mouse studies were being conducted, a further thirty 7-substituted oxazine 
derivatives were screened against L. don in the luciferase assay at CDRI.10 Based on the 
single IC50 data obtained for 14, 21-23, 25, 27-29, 34, 38, 39, 44, 45, 47, 49, and 52-54 
(Table 1), several preliminary SAR conclusions were drawn: (1) the 7-H series was generally 
5- to 10-fold more potent than the 7-methyl series; (2) 4-trifluoromethoxy and 4-benzyloxy 
substituents (forms A and C) provided equivalent potency; (3) for biaryl analogues (forms B 
and D), 4-fluoro was preferred over 4-trifluoromethoxy as the final ring substituent (as 
observed11 in the 6-nitroimidazooxazole series); (4) a shorter linker (forms C and D) was 
preferred in the majority of cases. Thus, the most active analogues appeared to be 14, 22, 25, 
39, 45, 49, and 53 (IC50s 0.01-0.06 µM, similar to 4). However, benzyl ether 14 did not 
display suitable metabolic stability (10% parent left after 1 h with MLM; Table 3), while 
evidence from the 6-substituted oxazine series17 for the more rapid metabolism of 
benzyloxybenzyl analogues dissuaded further testing of 22 and 45. Moreover, following the 
disappointing results with 28, we were not optimistic of good in vivo efficacy with close 
analogue 25, despite its improved potency. Therefore, we elected to initially investigate 39, 
49 and 53 as potential leads, together with two counterparts from the 7-methyl series, 44 and 
54, to enable a head-to-head comparison. 
The selected compounds were advanced to parallel mouse PK profiling and efficacy studies 
in the mouse VL model. Encouragingly, both phenyl ether 44 (the direct analogue of rac-4) 
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and biphenyl congener 49 showed excellent efficacy at 25 mg/kg (99.9-100% inhibition; 
Table 3 and Figure 3b). Surprisingly, the more potent 7-H counterpart of 44 (39) was slightly 
less active in this assay (87% inhibition), mimicking findings for the 2-H equivalent of rac-
4.11 Moreover, the biphenyl derivatives of 39 and 44 (53 and 54) were also less impressive 
than 49 (65% and 30% inhibition, respectively). However, while these latter results appeared 
to track well with the single determination L. don data, they did not seem to line up with the 
almost equivalent mean potencies vs L. inf (Table 1). The findings also appeared to conflict 
with the kinetic solubility and microsomal stability data (Table 3), where 49 was as poorly 
soluble as 28 (55 vs 58 ng/mL) but the more stable analogue 54 (85 vs 75% in MLM) was 
45-fold more soluble than 28 (2.6 µg/mL). Solubility is discussed further in the next section. 
Analysis of the mouse PK data (Table 4) provided greater insight, revealing that 39 had a 
4-fold higher rate of clearance than its 7-methyl derivative 44 (48 vs 12 mL/min/kg), 
resulting in a short half-life (1.1 h vs 2.8 h for 44) and quite poor oral exposure (see the 
Supporting Information, Figure S1). Interestingly, with iv administration, the PK profiles for 
44 and rac-4 were fairly similar, but 44 did not perform as well under oral dosing, with rather 
modest absorption (Cmax 1.4 µg/mL, 3-fold less than for rac-4) contributing to reduced 
exposure and moderate oral bioavailability (35% vs 79%). The oral parameters for compound 
54 were also mediocre (poor Cmax of 0.79 µg/mL and low oral bioavailability of 17% 
offsetting its lengthy 27 h half-life), potentially explaining its inferior efficacy in the mouse 
VL model. However, the findings for 49 and 53 were more puzzling, with the less efficacious 
53 demonstrating greater oral exposure (see the Supporting Information, Figure S1), superior 
oral bioavailability (100% vs 11% for 49), and an extended half-life (17 h vs 6.7 h for 49). 
Nevertheless, like 28, 53 was particularly hydrophobic (CLogP 5.03), so high PPB may be a 
major issue limiting its efficacy.42 We have previously observed that PK data is not always 
correctly predictive of in vivo efficacy ranking.43 
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These promising results prompted further appraisal of the most active compounds, 44 and 
49. In the mouse VL model, 44 provided robust dose-response data (Table 3), giving an ED50 
value of 4.2 mg/kg (cf. 3.0 mg/kg for rac-411). Unfortunately, additional studies of 49 in this 
model (using material prepared elsewhere) were unable to replicate the original result; we 
postulate that this discrepancy may be due in part to the extremely poor aqueous solubility 
and inadequate oral bioavailability of this compound, rendering oral suspension formulations 
particularly sensitive to particle size. Nevertheless, the optimal in vivo assay for assessing the 
efficacy of test compounds against VL is the chronic infection hamster model, which better 
reproduces the clinical pathology of human disease.44 In the L. don hamster model at CDRI, 
leads 44 and 49 were almost equally effective at 50 mg/kg, with 5 days of oral dosing leading 
to 53% and 51% inhibition of parasite infection in the spleen, whereas rac-4 gave 86% 
inhibition under the same dose regimen.11 
A significant factor in the suboptimal activity of 44 in the hamster model was thought to be 
its exceptionally rapid metabolism in this species, as revealed by the hamster microsomal 
stability data (only 16% remaining after 0.5 h vs 49% for rac-411). Therefore, 44 was later 
reassessed in the L. inf early curative hamster model at LMPH, comparing a twice-daily dose 
regimen (25 mg/kg b.i.d.) with a once-daily dose of 50 mg/kg. The results (Table 5) slightly 
favoured the twice-daily regimen for all 3 target organs; hence this protocol became standard 
for most test compounds. However, unlike 4, 44 was not curative at this dose level. Another 
liability with 44 was its greater inhibition of the hERG channel (IC50 3.8 µM vs 10.5 µM for 
4), with IC50 values in excess of 10 µM required to minimise QT prolongation risk.
45 Hence, 
as lead compounds for VL, 44 and 49 fulfilled many suggested criteria,46 but still had key 
deficiencies, reflecting their origin as screening hits in a scarcely studied new class. 
2. SAR of 7-substituted 2-nitroimidazooxazines for VL 
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Following the identification of 4 as a preferred drug candidate and the discovery of 44 and 
49 as unoptimised new leads, a backup program was launched to develop second generation 
agents for VL having better solubility, PK-PD and safety profile.11 Due to the inferior profile 
of 44 in comparison to 4 in several key areas, we elected to centre our synthetic strategy 
mainly on bicyclic side chains, employing heterocycles to modulate lipophilicity and 
solubility. Six-membered ring nitrogen-containing variants were preferred, due to their 
greater metabolic stability;47 ortho-substitution of aryl groups and meta-linkage of rings were 
also investigated as additional options to increase solubility.48 Recognising that few orally 
active registered drugs have solubility values below 1 µM at pH 7.4 (the pH of blood),49 we 
aspired to achieve at least 10-fold higher than this for the best compounds.46 We also aimed 
to exploit the low pH of gastric fluid (~1 to 2) to improve dissolution and oral absorption of 
analogues containing pyridine and other bases.50 Hence, we set a minimum solubility 
requirement for the preferred final candidate of being non-inferior to delamanid (5) (0.31 
µg/mL at pH 7 and 116 µg/mL at pH 1),11 an approved TB drug in Europe and Japan.12 
Based on the wider in vitro screening results, it was apparent that the 7-substituted oxazines 
could not be used for African trypanosomiasis (T. brucei IC50s mostly >64 µM, none <1 µM; 
see the Supporting Information, Tables S1 and S2). However, unlike the 6-
nitroimidazooxazoles, this new oxazine class generally showed interesting potencies against 
T. cruzi (IC50s 0.03-1 µM), suggesting the possibility of dual utility to treat both VL and 
Chagas disease. Further analysis of data for the 65 racemic compounds tested indicated a 
modest trend for the best VL leads to have high potencies against T. cruzi (see the Supporting 
Information, Figure S4). Hence, for simplicity, we will focus this part of the SAR discussion 
entirely on the intended primary application (VL), emphasising the key L. inf results. 
To begin with, a reanalysis of the initial dataset (up to and including 54; Table 1) 
confirmed weak trends on L. inf for the 7-H analogues to be more potent and a shorter linker 
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length to be preferred (e.g., 39: IC50 0.047 µM), but there was no consistent preference for 4-
fluoro as the terminal ring substituent. Nevertheless, in view of the better in vivo efficacy of 
49 and similarly substituted nitroimidazooxazoles,11 we retained this latter design element in 
the majority of cases. Thus, compounds 55 and 56 first investigated the effect of replacing the 
second phenyl ring of 49 by pyridine (CLogP -1.2 units). Pleasingly, this led to a 2- to 6-
fold potency increase, with 55 (IC50 0.083 µM) also being 6.5-fold more soluble than 49 
(0.36 vs 0.055 µg/mL, Table 3). Exchange of the first phenyl ring by 2-pyridine (59 and 61; 
CLogP -0.5 units) resulted in even better activity (59: IC50 0.050 µM), and in this case 
solubility values were ~20-fold higher at low pH (2.8-13 µg/mL; calcd pKa 2.83), although 
still rather modest. Therefore, we examined the addition of an ortho fluorine in the phenyl 
ring (62 and 63), in an attempt to break up the planarity.48 However, while this change was 
well tolerated, there was no improvement in solubility and microsomal stability was reduced 
(19% vs 43% in MLM for 62 vs 59, Table 3). In an alternative approach, we tried meta-
linkage of the rings (99 and 101-103), but although the activity was generally acceptable, this 
led to inferior solubility (99: 27 ng/mL). 
Turning instead to 3-pyridine as a first ring, potency was maximised by 2,4-difluorophenyl 
substitution (91: IC50 0.030 µM), although the 4-fluoro and 4-trifluoromethoxy (7-H) 
analogues (71 and 93) were also useful (IC50s 0.093 and 0.12 µM, respectively). Importantly, 
aqueous solubility values were up to 13-fold better than for 49 at neutral pH (91: 0.72 µg/mL) 
and 3 orders of magnitude better at low pH (91: 221 µg/mL). This was consistent with a 
greater lipophilicity reduction for the 3-pyridine (CLogP -1.1 units) and a slightly higher 
basicity (e.g., 71: calcd pKa 3.76). Final assessment of the enantiomers of two examples, 71 
and 93, identified the R forms (79 and 94) as slightly preferred for both potency and 
microsomal stability (particularly in the case of 79). 
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In view of the promising results with phenylpyridines, we elected to investigate the more 
hydrophilic bipyridines (105-120). Most of these showed interesting potencies in the initial L. 
don screen and further assessments had identified 108, 112, and 113 as being of potential 
interest, based on their improved solubilities in comparison to 49 (2.3-4.5 vs 0.055 µg/mL). 
However, on retesting, almost all of the 7-H compounds displayed markedly inferior utility 
against L. inf (IC50s 2.5 to >64 µM) while the 7-methyl bipyridines retained moderate 
potencies (IC50s 0.20-1.1 µM). It is intriguing to speculate that this might indicate a 
“minimum lipophilicity” requirement for activity (e.g., CLogP ~2.5) because a similar pattern 
was noted for all of the more hydrophilic analogues (see analysis of racemic 7-H dataset, 
Figure 4). Another strategy for heterobiaryl analogues of 49 was to exchange the first phenyl 
ring with pyridazine, pyrazine, or pyrimidine (123, 126, 129, 131-133, and 139). Of these, 
pyrimidine (129, 131, and 139) provided the best activity (IC50s 0.21-0.29 µM), although 
combining this with a pyridine ring (132, 133) led to a dramatic loss of potency (21- to >220-
fold). Overall, pyrimidine 129 had the best aqueous solubility (1.8 µg/mL; 33-fold better than 
49), along with acceptable metabolic stability. 
More structurally diverse targets (142, 144, 147, 149, 152, 154, 157, 159-161, 170, and 
178; Table 2) were designed on the premise that arylated cyclic amines can be effective 
bioisosteres for biphenyls, thus facilitating substantial boosts in solubility.51,52 Several side 
chains of this type have previously shown promise for TB and/or VL,11,18 including in the 
recent development of antileishmanial aminopyrazole ureas.53 It was initially encouraging to 
see four examples (arylpiperazine 142, aryloxypiperidines 152 and 154, and arylpiperazine 
carbamate 161) exhibiting reasonable potencies in the L. don screen (IC50s 0.19-0.45 µM), 
with 142 and 152 displaying a markedly better solubility profile than 49 (10-49 µg/mL at pH 
7, 15-21 mg/mL at low pH). However, the L. inf data did not fully match the L. don results; 
instead, the 7-methyl analogues were clearly favoured over the 7-H compounds (by 3- to 7-
16 
 
fold) and the more lipophilic piperidines 149 and 154 were superior (IC50s 0.32 µM). The 
hydrophilic benzoylpiperazines 157 and 159 were particularly poor in both assays, as was the 
7-H arylpiperazine carbamate 160. In view of these SAR findings, two O-linked 
phenylpiperidines (170 and 178) were subsequently designed as structurally closer mimetics 
for the O-linked biphenyl 49. Gratifyingly, 170 demonstrated both good potency (IC50 0.24 
µM) and much better solubility than 49 (6.1 µg/mL at pH 7, 34 mg/mL at pH 1); albeit, the 
microsomal stability of this compound (17-33% in MLM and HLM) was regarded as quite 
marginal. 
Integration of the initial L. don data with the kinetic solubility and microsomal stability 
results led to the selection of 9 new racemic analogues of 49 for testing in the L. don mouse 
model (dosing at 50 mg/kg for 5 d; Table 3 and Figure 3a). Encouragingly, a first experiment 
on 3-pyridine derivative 71 (4-FPh) yielded a 100% parasite clearance from the liver in all 
mice. Following this, 4-trifluoromethoxy congener 93 was found to be equally efficacious 
(99.5%), whereas the 2,4-difluoro example 91 was slightly less effective (91% inhibition). 
However, the less potent 7-methyl derivative of 71 (90) and the more potent 2-pyridine 
analogue 59 were only moderately active (41% and 67%, respectively); it is possible that the 
higher crystallinity (larger particle size) of 59 may have contributed to poor oral 
bioavailability.42,48 Two more soluble heterobiaryl analogues, bipyridine 112 and 
phenylpyrimidine 129, also displayed lower efficacy (44% and 85% inhibition); oral PK data 
on 112 (Table 4 and Supporting Information, Figure S2) were comparable to those of 71 so 
this may be a potency issue (as suggested by the disparate L. inf and L. don IC50s of >64 vs 
0.09 µM). Finally, the inferior in vivo outcomes for two potential bioisosteres of 49, 
phenylpiperazine 142 (55%) and O-linked phenylpiperidine 170 (45%), may be attributed to 
either weaker in vitro activity on retesting (for 142: L. inf IC50 2.3 µM) or more rapid 
metabolism (for 170), as indicated above. No adverse effects were noted in any of the in vivo 
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experiments and the percentage weight changes for the mice were well within normal 
thresholds (see the Supporting Information, Table S4). 
Dose-response appraisal of 71 in this mouse model provided an ED50 value of 5.1 mg/kg 
(cf. 4.2 mg/kg for 44) whereas the trifluoromethoxy analogue 93 was unexpectedly ~3-fold 
better (50% at 1.56 mg/kg; Table 3). Therefore, the enantiomers of both 71 and 93 were 
assessed and in each case the R form (79 and 94) gave higher efficacy, with 94 (84% at 1.56 
mg/kg) outperforming the preclinical candidate 4 (49%). Meanwhile, 71 was further 
evaluated in the L. inf hamster model at LMPH. A dose regimen of 25 or 12.5 mg/kg b.i.d. for 
5 days enabled parasite burden reductions exceeding 99% for all 3 target organs (Table 5 and 
Figure 5), similar to 4 at 25 mg/kg once daily (q.d.). However, 71 was slightly less effective 
than 4 when given via the 12.5 mg/kg q.d. schedule. A final head-to-head comparison of the 
enantiomers of 71 confirmed 79 as the preferred stereoisomer, based on its superior efficacy 
at two dose levels. This result was also supported by favourable PK data e.g., a higher 
exposure than 87 in hamsters, with an acceptable half-life (3.1 h) and good oral 
bioavailability (34%) in the rat (Table 4 and Supporting Information, Figure S3). Although 
94 was not tested in the hamster model, it is thought that 79 may still offer some advantages 
as a lead candidate e.g., lower lipophilicity (by ~1 log unit) and reduced molecular weight 
(this could lessen PPB and improve safety),42 slightly better solubility (a calculated pKa value 
of 3.76 vs 3.42 for 94), and a physical form more suitable for oral administration. 
In line with our initial objective to develop improved drug candidates as backups to 4, it 
was pertinent to examine some additional properties of 79 (Table 6). Compared to 4, 79 had a 
very similar molecular weight (370 vs 359 Da) and provided thermodynamic solubility values 
that were clearly superior to 4 as the pH approached the measured pKa value of 3.95. It also 
had a lower experimental LogD value (2.45 vs 3.10), close to that of pretomanid (6).18 
Furthermore, like 4,54 79 displayed high permeability (without being a substrate for P-gp 
18 
 
mediated efflux), although it did show a slightly greater binding to human plasma proteins 
(96.5 vs 93.9%). In terms of safety, 79 gave a low inhibition of hERG (IC50 >30 µM), did not 
inhibit CYP3A4 (IC50 >100 µM), and was not mutagenic (Ames test). These characteristics 
broadly match the suggested criteria for clinical development of a new entity for VL,55 so 
following a belated concern with 4, 79 has now been selected as a new preclinical candidate. 
3. SAR of 7-substituted 2-nitroimidazooxazines for TB 
Although the primary goal of our work with DNDi was a new drug for VL, the series was 
originally designed and exemplified for TB, seeking a novel second-generation backup to 6 
(now in phase II/III clinical trials13). Hence, the antitubercular activities of the 7-substituted 
oxazine derivatives have remained an aspect of significant ongoing interest. The work began 
with the preparation of an exploratory set of four compounds (14, 22, 39, and 45; Table 1). 
Growth inhibitory effects against Mycobacterium tuberculosis (M. tb, strain H37Rv) were 
studied under both aerobic (replicating) and hypoxic (non-replicating) conditions (MABA41 
and LORA56 assays, respectively), in recognition of the varying modes of action of 6 under 
each state,57 and the suggestion that optimising for hypoxic activity may lead to agents with 
better sterilizing ability against persistent bacteria;56 recorded MIC data (for at least 90% 
inhibition) represent the mean of 2-5 independent measurements. Compared with racemic 6 
(MICs of 1.1 and 4.4 µM in MABA and LORA, respectively),14 compounds 14 and 22 
showed potencies of similar magnitude, stimulating further interest and the synthesis of more 
than 30 new analogues, including 21, 23, 25, 27-29, 44, 47, 49, and 52-54 (Table 1). These 
featured two design elements that had proven most advantageous for enhancing in vivo 
efficacy in early studies of 4 and 6, namely, biaryl extension, and methylation adjacent to the 
ring oxygen.11,30,58 
From this larger dataset, it was observed that 7-methyl congeners (e.g., 21, 23, 44, and 47) 
were generally slightly more effective than 7-H counterparts, and that biphenyl side chains 
19 
 
(e.g., 25, 27-29, 49, and 52-54) provided roughly an order of magnitude further improvement 
in MABA MIC values (whereas LORA data were less responsive to these changes). The 
phenylbenzyl derivative 29 was earmarked as a potential early lead, based on its better MIC 
profile (0.093 and 1.4 µM in MABA and LORA) and good stability toward MLM and HLM 
(77-85% parent remaining after a 1 h exposure, Table 3). Thus, for preliminary proof of 
principle, the enantiomers of 29 (34 and 38) were prepared and assessed in the acute TB 
infection mouse model alongside 6, dosing orally at 100 mg/kg daily (5 days/week) for 3 
weeks. In this experiment, the R enantiomer 34 displayed equivalent efficacy to 6, but the S 
form 38 was 5-fold less active (Figure 6), in accordance with its weaker potency and MLM 
stability data. Nevertheless, the very high lipophilicity of 34 (CLogP 5.52) and its inferior PK 
profile in comparison to the shorter linked analogue 53 (Table 4) imply that far better in vivo 
effects might be achievable with optimised compounds (as shown for VL; cf., 94 vs 28). 
The early preference for 7-methyl substitution was not a consistent pattern across 
heterobiaryl derivatives, where the most potent examples, notably phenylpyridines 59, 64, 93 
and 94, as well as phenylpyrimidine 129 (MABA MICs 0.02-0.04 µM) were 7-H compounds. 
As found for the 6-substituted series,16 bipyridine and other heterobiaryl analogues were 
generally less impressive (except the 4-CF3 congener 111), particularly when the rings were 
meta-linked (corresponding phenylpyridines 99 and 101-103 also displayed markedly 
reduced activity). Finally, arylated cyclic amine bioisosteres (Table 2) showed moderate to 
weak potencies overall, with the hydrophilic benzoylpiperazines 157 and 159 being 
especially poor. For side chains A-C, 7-methyl compounds exhibited an order of magnitude 
better aerobic activity than their 7-H counterparts, although LORA results were disappointing 
for these and the related O-linked phenylpiperidines (170 and 178). Nevertheless, it was 
recognised that most of these new 7-substituted oxazines possessed a 4-fluoro substituted 
terminal ring, whereas more lipophilic 4-trifluoromethoxyphenyl (or 4-CF3pyridine) termini 
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were favoured for TB16-18,43,58 (as seen for phenylpyridines 93-95 vs 71, 79, and 87). 
Therefore, a few additional examples of the latter type (189-194 and 198: Supporting 
Information, Table S3) were also made and evaluated. Here, 191 and 198 (4-OCF3) were 10- 
to 16-fold more effective than 123 and 139 (4-F) in both TB assays (192-194 were also 2- to 
8-fold better than 126, 129, and 131 in MABA), confirming this same SAR pattern. Overall, 
taking into account potency46 (needing to be superior to 511), solubility and metabolism 
effects, it is considered that phenylpyridine 94 is the most promising lead for TB. 
CONCLUSIONS 
Through a scaffold hopping design strategy, 7-substituted 2-nitroimidazooxazines were 
identified as a third, highly active nitroimidazole-based class of antitubercular agents, having 
a remarkable similarity in properties to 2-substituted 6-nitroimidazooxazoles. Phenotypic 
screening of some unoptimised early examples against kinetoplastid diseases led to the 
detection of two compounds (44 and 49) having significant efficacy against VL in mouse and 
hamster models, although these proved to be inferior to preclinical lead 4 as potential drug 
candidates. Based on our experiences in the original two classes (with 4 and 6), we then 
sought to develop more suitable second-generation agents for VL by systematically exploring 
heterocyclic side chain variants of biphenyl lead 49. Replacement of one or both phenyl rings 
by pyridine (or pyrimidine etc.) enabled large modulations in lipophilicity (CLogP -0.5 
to -2.7 units), with concomitant improvements in aqueous solubility (2- to 71-fold at pH 7 
and ~4000-fold at pH 1 for phenyl-3-pyridines). In a complementary bioisostere approach, 
the incorporation of piperazine or piperidine for the first ring produced even greater solubility 
enhancements (e.g., 170: 34 mg/mL at low pH). However, more subtle strategies (viz. ortho-
substitution of aryl groups and meta-linkage of aryl rings) proved less beneficial overall. 
Interestingly, potency against L. inf appeared to show some dependence on lipophilicity, 
with the most effective 7-H compounds falling in a CLogP range of 2.9-4.0, and compounds 
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of CLogP <2.5 having weak or negligible activity. This was aptly demonstrated by the 
improved potency of fluorinated phenylpyridines (5- to 16-fold over 49), in which the 
pyridine could be either terminal or proximal to the linker, whereas the combination of two 
pyridine rings was strongly deactivating, except in the presence of a 7-methyl substituent. 
Phenylpyrimidine and phenylpiperidine were the only other side chains to provide substantial 
activity in this assay. It has recently been shown59 that a novel nitroreductase (NTR2) in 
Leishmania is responsible for the activation of nitroimidazooxazoles such as 4; therefore, 
differential nitroreductase binding may be a major factor behind the in vitro SARs for both 
VL and TB.57 Evaluation of a representative set of nine racemic compounds in the VL mouse 
model pinpointed phenylpyridines 71 and 93 as the most efficacious, with 93 being as 
impressive as 4 (50% inhibition at 1.56 mg/kg). In the chronic infection L. inf hamster model, 
71 (at 12.5 mg/kg b.i.d.) achieved >99% reductions in parasite burden for all 3 target organs. 
Subsequent synthesis and assessment of the enantiomers of both leads identified the R forms 
(79 and 94) as superior, and in the case of 79 this outcome was reinforced by excellent results 
in the L. inf hamster model and favourable PK data in the hamster and rat. Importantly, 79 
(DNDI-0690) also provided a better safety profile than 4 and has now been selected as a new 
preclinical candidate for VL. 
Finally, as found for the nitroimidazooxazole series,11 it was intriguing to note that some of 
the best VL leads (e.g., 59, 79, 93, 94, and 129) showed highly potent in vitro effects against 
TB, with both R enantiomers and 4-trifluoromethoxy analogues most preferred, pointing to 
94 (MABA MIC 0.024 µM) as the favoured TB candidate for further evaluation. The S form 
of 93 (95) also displayed interesting activity against T. cruzi (IC50 0.13 µM), indicating a 
possible application for treating Chagas disease. This investigation has therefore revealed that 
the 7-substituted 2-nitroimidazooxazine class has exciting potential to treat up to 3 neglected 
diseases and can deliver drug candidates that are worthy of examination in ongoing studies. 
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EXPERIMENTAL SECTION 
Combustion analyses were performed by the Campbell Microanalytical Laboratory, 
University of Otago, Dunedin, New Zealand. Melting points were determined using an 
Electrothermal IA9100 melting point apparatus, and are as read. NMR spectra were measured 
on a Bruker Avance 400 spectrometer at 400 MHz for 1H and 100 MHz for 13C and are 
referenced to Me4Si or solvent resonances. Chemical shifts and coupling constants are recorded 
in units of ppm and hertz, respectively. High-resolution fast atom bombardment (HRFABMS) 
mass spectra were determined on a VG-70SE mass spectrometer at nominal 5000 resolution. 
High-resolution electrospray ionisation (HRESIMS) mass spectra were determined on a 
Bruker micrOTOF-Q II mass spectrometer. Low-resolution atmospheric pressure chemical 
ionisation (APCI) mass spectra were obtained for organic solutions using a ThermoFinnigan 
Surveyor MSQ mass spectrometer, connected to a Gilson autosampler. Optical rotations were 
measured on a Schmidt + Haensch Polartronic NH8 polarimeter. Column chromatography 
was performed on silica gel (Merck 230-400 mesh). Thin-layer chromatography was carried out 
on aluminium-backed silica gel plates (Merck 60 F254), with visualization of components by UV 
light (254 nm), I2, or KMnO4 staining. Tested compounds (including batches screened in vivo) 
were ≥95% pure, as determined by combustion analysis (results within 0.4% of theoretical 
values) and/or by HPLC conducted on an Agilent 1100 system, using a 150 mm x 3.2 mm 
Altima 5 µm reversed phase C18 column with diode array detection. Preparative reversed 
phase HPLC was performed using a Gilson Unipoint system (322-H pump, 156 UV/vis 
detector) with 250 mm x 21 mm Synergi Max-RP 4 µm C12 or Zorbax 7 µm SB-C18 
columns. Finally, preparative chiral HPLC was carried out on similar equipment by 
employing a 250 mm x 20 mm CHIRALPAK IA 5 µm semi-preparative column, while chiral 
purity was assessed using 250 mm x 4.6 mm CHIRALPAK IA or CHIRALPAK AS-H 5 µm 
analytical columns. 
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Compounds of Table 1. The following section details the syntheses of compounds 14, 25, 
34, 44, 55, 59, and 79 of Table 1, via representative procedures and key intermediates, as 
described in Schemes 1-3. For the syntheses of all of the other compounds in Table 1, please 
refer to the Supporting Information. 
Synthesis of 14 (Scheme 1A): 
Procedure A: 2-Bromo-1-(but-3-en-1-yl)-4-nitro-1H-imidazole (9). A mixture of 2-
bromo-4-nitro-1H-imidazole (8) (2.50 g, 13.0 mmol), 4-bromobut-1-ene (2.00 mL, 19.7 
mmol), and powdered K2CO3 (5.39 g, 39.0 mmol) in anhydrous DMF (25 mL) under N2 was 
stirred at 73 °C for 4.5 h. The resulting cooled mixture was added to ice/aqueous NaHCO3 
(200 mL) and extracted with EtOAc (4 x 200 mL). The extracts were washed with water (200 
mL) and then evaporated to dryness under reduced pressure (at 30 C) and the residue was 
chromatographed on silica gel. Elution with 0-10% EtOAc/petroleum ether first gave foreruns, 
and then further elution with 20% EtOAc/petroleum ether gave 9 (2.96 g, 92%) as a pale 
yellow oil that solidified on cooling: mp 28-30 C; 1H NMR (CDCl3)  7.77 (s, 1 H), 5.75 
(ddt, J = 17.1, 10.2, 6.9 Hz, 1 H), 5.18 (dq, J = 10.2, 1.1 Hz, 1 H), 5.12 (dq, J = 17.1, 1.4 Hz, 
1 H), 4.09 (t, J = 7.0 Hz, 2 H), 2.58 (qt, J = 6.9, 1.2 Hz, 2 H); HRFABMS calcd for 
C7H9BrN3O2 m/z [M + H]
+ 247.9858, 245.9878, found 247.9860, 245.9882. 
Procedure B: 4-(2-Bromo-4-nitro-1H-imidazol-1-yl)butane-1,2-diol (10). Osmium 
tetroxide (3.20 mL of a 4% aqueous solution, 0.524 mmol) was added to a solution of alkene 
9 (2.56 g, 10.4 mmol) and 4-methylmorpholine 4-oxide (1.83 g, 15.6 mmol) in CH2Cl2 (65 
mL). The mixture was stirred at 20 C for 4 h and the resulting precipitate was collected by 
filtration, washing with CH2Cl2 and water, to give 10 (2.29 g, 79%) as a cream solid: mp 
(THF/Et2O/pentane) 99-101 C; 1H NMR [(CD3)2SO]  8.55 (s, 1 H), 4.77 (br d, J = 5.0 Hz, 
1 H), 4.58 (br t, J = 5.6 Hz, 1 H), 4.20-4.07 (m, 2 H), 3.47-3.37 (m, 1 H), 3.34 (dt, J = 10.7, 
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5.4 Hz, 1 H), 3.24 (dt, J = 10.7, 5.9 Hz, 1 H), 2.03-1.92 (m, 1 H), 1.76-1.63 (m, 1 H). Anal. 
(C7H10BrN3O4) C, H, N. 
The remaining filtrate above was added to an ice-cold aqueous solution of sodium sulphite 
(100 mL), and the aqueous portion was saturated with salt and extracted with EtOAc (10 x 
100 mL). The combined organic portions were evaporated to dryness under reduced pressure 
(at 30 C), and the residue was chromatographed on silica gel. Elution with 0-50% 
EtOAc/petroleum ether first gave foreruns, and then further elution with EtOAc gave 
additional 10 (572 mg, 20%). 
Procedure C: 4-(2-Bromo-4-nitro-1H-imidazol-1-yl)-1-[(triisopropylsilyl)oxy]butan-2-
ol (11). Chlorotriisopropylsilane (2.35 mL, 11.0 mmol) was slowly added to a solution of diol 
10 (2.86 g, 10.2 mmol) and imidazole (1.54 g, 22.6 mmol) in anhydrous DMF (25 mL) under 
N2, and then the mixture was stirred at 20 C for 2 d. The resulting mixture was added to ice-
water (150 mL) and extracted with 50% EtOAc/petroleum ether (4 x 100 mL). The extracts 
were washed with water (100 mL) and then concentrated under reduced pressure (at 30 C) 
and the remaining oil was chromatographed on silica gel. Elution with 0-20% 
EtOAc/petroleum ether first gave foreruns, and then further elution with 33% 
EtOAc/petroleum ether gave 11 (4.19 g, 94%) as a white solid: mp (CH2Cl2/pentane) 90-91 
C; 1H NMR (CDCl3)  7.89 (s, 1 H), 4.24 (dd, J = 7.7, 6.2 Hz, 2 H), 3.74 (dd, J = 9.6, 3.5 
Hz, 1 H), 3.67-3.58 (m, 1 H), 3.53 (dd, J = 9.6, 6.8 Hz, 1 H), 2.59 (d, J = 3.8 Hz, 1 H), 1.95-
1.82 (m, 2 H), 1.18-1.02 (m, 21 H). Anal. (C16H30BrN3O4Si) C, H, N. 
Procedure D: 2-Nitro-7-{[(triisopropylsilyl)oxy]methyl}-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (12). A solution of alcohol 11 (1.89 g, 4.33 mmol) in anhydrous DMF (35 
mL) under N2 at 0 C was treated with 60% NaH (262 mg, 6.55 mmol) and then quickly 
degassed and resealed under N2. The mixture was stirred at 0 C for 25 min and at 20 C for 3 
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h, then cooled (CO2/acetone), quenched with ice/aqueous NaHCO3 (10 mL), added to brine 
(100 mL), and extracted with CH2Cl2 (6 x 100 mL). The combined extracts were evaporated 
to dryness under reduced pressure (at 30 C) and the residue was chromatographed on silica 
gel. Elution with 0-20% EtOAc/petroleum ether first gave foreruns, and then further elution 
with 0-4% EtOAc/CH2Cl2 gave 12 (1.48 g, 96%) as a pale yellow solid: mp (CH2Cl2/pentane) 
121-123 C; 1H NMR (CDCl3)  7.42 (s, 1 H), 4.49-4.40 (m, 1 H), 4.17 (ddd, J = 12.3, 5.8, 
3.7 Hz, 1 H), 4.06 (ddd, J = 12.3, 10.3, 5.4 Hz, 1 H), 4.03 (dd, J = 10.7, 4.1 Hz, 1 H), 3.95 
(dd, J = 10.7, 5.8 Hz, 1 H), 2.42-2.33 (m, 1 H), 2.33-2.20 (m, 1 H), 1.18-1.03 (m, 21 H). 
Anal. (C16H29N3O4Si) C, H, N. 
Procedure E: (2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methanol (13). 
Silyl ether 12 (1.48 g, 4.16 mmol) was treated with a solution of 1% HCl in 95% EtOH27 (63 
mL, 15.1 mmol). The mixture was stirred at 20 C for 36 h and then cooled (CO2/acetone) 
and neutralised with a solution of NH3 in MeOH (8.0 mL of 2 M). The resulting mixture was 
evaporated to dryness under reduced pressure (at 30 C) and the residue was 
chromatographed on silica gel. Elution with 0-2% MeOH/CH2Cl2 first gave foreruns and then 
further elution with 2-4% MeOH/CH2Cl2 gave 13 (804 mg, 97%) as a light yellow solid: mp 
(THF/MeOH/CH2Cl2/hexane) 179-181 C; 1H NMR [(CD3)2SO]  8.04 (s, 1 H), 5.12 (t, J = 
5.8 Hz, 1 H), 4.53-4.43 (m, 1 H), 4.13 (ddd, J = 12.5, 5.8, 3.0 Hz, 1 H), 4.04 (ddd, J = 12.4, 
11.0, 5.1 Hz, 1 H), 3.70-3.59 (m, 2 H), 2.23-2.13 (m, 1 H), 2.10-1.96 (m, 1 H). Anal. 
(C7H9N3O4) C, H, N. 
Procedure F: 2-Nitro-7-({[4-(trifluoromethoxy)benzyl]oxy}methyl)-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (14). A solution of alcohol 13 (40.2 mg, 0.202 mmol) in 
anhydrous DMF (2 mL) under N2 at 0 C was treated with 60% NaH (13.7 mg, 0.343 mmol) 
and then quickly degassed and resealed under N2. 4-(Trifluoromethoxy)benzyl bromide (60 
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µL, 0.375 mmol) was added, and the mixture was stirred at 20 C for 165 min, then cooled 
(CO2/acetone), quenched with ice/aqueous NaHCO3 (10 mL), added to brine (40 mL), and 
extracted with CH2Cl2 (6 x 50 mL). The combined extracts were evaporated to dryness under 
reduced pressure (at 30 C) and the residue was chromatographed on silica gel. Elution with 
0-0.5% MeOH/CH2Cl2 first gave foreruns, and then further elution with 0.5% MeOH/CH2Cl2 
gave 14 (52 mg, 69%) as a cream solid: mp (CH2Cl2/hexane) 158-160 C; 1H NMR 
[(CD3)2SO]  8.06 (s, 1 H), 7.47 (br d, J = 8.7 Hz, 2 H), 7.35 (br d, J = 7.9 Hz, 2 H), 4.77-
4.69 (m, 1 H), 4.60 (s, 2 H), 4.13 (ddd, J = 12.5, 5.8, 3.0 Hz, 1 H), 4.05 (ddd, J = 12.5, 10.8, 
5.2 Hz, 1 H), 3.76 (dd, J = 11.1, 3.9 Hz, 1 H), 3.73 (dd, J = 11.1, 5.1 Hz, 1 H), 2.27-2.17 (m, 
1 H), 2.17-2.03 (m, 1 H); 13C NMR [(CD3)2SO]  147.9, 147.6 (q, JC-F = 1.4 Hz), 142.0, 
137.6, 129.2 (2 C), 120.9 (2 C), 120.1 (q, JC-F = 256.0 Hz), 117.7, 76.7, 71.4, 70.9, 41.8, 22.6. 
Anal. (C15H14F3N3O5) C, H, N. 
Synthesis of 25 (Scheme 1B): 
Procedure G: 7-{[(4-Iodobenzyl)oxy]methyl}-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (24). A mixture of alcohol 13 (130 mg, 0.653 mmol) and 4-iodobenzyl 
bromide (262 mg, 0.882 mmol) in anhydrous DMF (5 mL) under N2 at 0 C was treated with 
60% NaH (40 mg, 1.00 mmol) and then quickly degassed and resealed under N2. The mixture 
was stirred at 20 C for 2.5 h, then cooled (CO2/acetone), quenched with ice/aqueous 
NaHCO3 (10 mL), added to brine (40 mL), and extracted with CH2Cl2 (5 x 50 mL). The 
combined extracts were evaporated to dryness under reduced pressure (at 30 C) and the 
residue was chromatographed on silica gel. Elution with CH2Cl2 first gave foreruns, and then 
further elution with 1-1.5% EtOAc/CH2Cl2 gave 24 (165 mg, 61%) as a cream solid: mp 
(CH2Cl2/hexane) 169-171 C; 1H NMR (CDCl3)  7.68 (br d, J = 8.3 Hz, 2 H), 7.41 (s, 1 H), 
7.05 (br d, J = 8.2 Hz, 2 H), 4.59-4.52 (m, 3 H), 4.14 (ddd, J = 12.3, 5.7, 3.8 Hz, 1 H), 4.05 
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(ddd, J = 12.3, 10.0, 5.6 Hz, 1 H), 3.80 (dd, J = 10.6, 4.3 Hz, 1 H), 3.75 (dd, J = 10.6, 5.0 
Hz, 1 H), 2.37-2.20 (m, 2 H); HRFABMS calcd for C14H15IN3O4 m/z [M + H]
+ 416.0107, 
found 416.0105. 
Procedure H: 7-{[(4'-Fluoro[1,1'-biphenyl]-4-yl)methoxy]methyl}-2-nitro-6,7-dihydro-
5H-imidazo[2,1-b][1,3]oxazine (25). A stirred mixture of iodide 24 (35 mg, 0.084 mmol), 4-
fluorophenylboronic acid (15.8 mg, 0.113 mmol), and Pd(dppf)Cl2 (2.1 mg, 0.003 mmol) in 
toluene (1.8 mL) and EtOH (0.7 mL) was degassed for 5 min (vacuum pump) and then N2 
was added. An aqueous solution of Na2CO3 (0.35 mL of 2 M, 0.70 mmol) was added by 
syringe and the mixture was stirred at 90 C for 20 min, and then cooled, diluted with 
aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (4 x 50 mL). The extracts were 
evaporated to dryness under reduced pressure (at 30 C) and the residue was 
chromatographed on silica gel. Elution with 0-1% EtOAc/CH2Cl2 first gave foreruns, and 
then further elution with 1-1.5% EtOAc/CH2Cl2 gave 25 (30.5 mg, 94%) as a cream solid: mp 
(CH2Cl2/pentane) 147-149 C; 1H NMR [(CD3)2SO]  8.07 (s, 1 H), 7.71 (br dd, J = 8.9, 5.4 
Hz, 2 H), 7.64 (br d, J = 8.2 Hz, 2 H), 7.43 (br d, J = 8.3 Hz, 2 H), 7.29 (br t, J = 8.9 Hz, 2 
H), 4.77-4.69 (m, 1 H), 4.61 (s, 2 H), 4.13 (ddd, J = 12.5, 5.8, 3.0 Hz, 1 H), 4.05 (ddd, J = 
12.4, 10.9, 5.2 Hz, 1 H), 3.77 (dd, J = 11.0, 3.9 Hz, 1 H), 3.74 (dd, J = 11.1, 5.1 Hz, 1 H), 
2.28-2.17 (m, 1 H), 2.17-2.03 (m, 1 H); 13C NMR [(CD3)2SO]  161.9 (d, JC-F = 244.4 Hz), 
148.0, 142.0, 138.4, 137.2, 136.3 (d, JC-F = 3.0 Hz), 128.6 (d, JC-F = 8.1 Hz, 2 C), 128.1 (2 C), 
126.6 (2 C), 117.7, 115.7 (d, JC-F = 21.2 Hz, 2 C), 76.8, 72.0, 70.8, 41.8, 22.6. Anal. 
(C20H18FN3O4) C, H, N. 
Synthesis of 34 (Scheme 1C): 
(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl acetate (30). 
Acetic anhydride (3.60 mL, 38.1 mmol) was added to a suspension of alcohol 20 (see 
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Supporting Information) (807 mg, 3.79 mmol) in anhydrous pyridine (7.0 mL). The mixture 
was stirred at 20 C for 38 h and then added to ice-water (150 mL) and extracted with CH2Cl2 
(5 x 100 mL). The extracts were evaporated to dryness under reduced pressure (at 30 C) and 
the residue was chromatographed on silica gel. Elution with CH2Cl2 first gave foreruns, and 
then further elution with 1-6% EtOAc/CH2Cl2 gave 30 (962 mg, 100%) as a cream solid: mp 
(CH2Cl2/pentane) 145-147 C; 1H NMR (CDCl3)  7.44 (s, 1 H), 4.27 (d, J = 11.9 Hz, 1 H), 
4.20 (d, J = 11.9 Hz, 1 H), 4.14 (dt, J = 12.7, 5.9 Hz, 1 H), 4.08 (ddd, J = 12.7, 8.3, 5.6 Hz, 1 
H), 2.32 (ddd, J = 14.5, 8.3, 6.1 Hz, 1 H), 2.10 (dt, J = 14.5, 5.7 Hz, 1 H), 2.09 (s, 3 H), 1.50 
(s, 3 H); HRFABMS calcd for C10H14N3O5 m/z [M + H]
+ 256.0934, found 256.0941. 
[(7R)-7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl]methyl acetate 
(31) and [(7S)-7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl]methyl 
acetate (35). Racemic acetate 30 (990 mg) was separated into pure enantiomers by preparative 
chiral HPLC, using a CHIRALPAK IA column and an isocratic solvent system of 40% EtOH 
in hexane at a flow rate of 6 mL/min, to firstly give 35 (427 mg, 43%) as a cream solid, 
having identical 1H NMR data to 30, that was used directly in the next step; [α]26D -6.0 (c 
1.00, CHCl3). 
Further elution of the HPLC column gave 31 (428 mg, 43%) as a cream solid that was used 
directly in the next step; 1H NMR (CDCl3)  7.44 (s, 1 H), 4.27 (d, J = 11.9 Hz, 1 H), 4.20 
(d, J = 11.8 Hz, 1 H), 4.14 (dt, J = 12.7, 5.9 Hz, 1 H), 4.08 (ddd, J = 12.7, 8.3, 5.6 Hz, 1 H), 
2.32 (ddd, J = 14.5, 8.3, 6.1 Hz, 1 H), 2.10 (dt, J = 14.5, 5.7 Hz, 1 H), 2.09 (s, 3 H), 1.50 (s, 
3 H); [α]26D 6.0 (c 1.00, CHCl3). 
Chiral HPLC (using a CHIRALPAK IA analytical column and eluting with 40% EtOH in 
hexane at 0.5 mL/min) determined that the ee of each enantiomer was 100%. 
Procedure I: [(7R)-7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-
yl]methanol (32). A stirred solution of ester 31 (427 mg, 1.67 mmol) in MeOH (36 mL) was 
29 
 
treated with K2CO3 (256 mg, 1.85 mmol) and then water (4 mL) was added dropwise. The 
mixture was stirred at 20 C for 4 h and then cooled in ice and neutralised with 0.1 M HCl 
(37 mL). The resulting mixture was evaporated to dryness under reduced pressure (at 30 C) 
and the residue was chromatographed on silica gel. Elution with 0-1% MeOH/CH2Cl2 first 
gave foreruns and then further elution with 1-2.5% MeOH/CH2Cl2 gave 32 (343 mg, 96%) as 
a light yellow solid that was used directly in the next step; 1H NMR [(CD3)2SO]  8.03 (s, 1 
H), 5.23 (br t, J = 5.4 Hz, 1 H), 4.13 (dt, J = 13.0, 6.0 Hz, 1 H), 4.05 (ddd, J = 12.9, 8.1, 5.6 
Hz, 1 H), 3.54 (dd, J = 11.6, 4.9 Hz, 1 H), 3.48 (dd, J = 11.6, 5.2 Hz, 1 H), 2.21 (ddd, J = 
14.4, 8.1, 5.9 Hz, 1 H), 2.00 (dt, J = 14.4, 5.8 Hz, 1 H), 1.32 (s, 3 H); [α]27D -18.0 (c 1.00, 
DMF). 
(7R)-7-{[(4-Bromobenzyl)oxy]methyl}-7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (33). Reaction of alcohol 32 with 4-bromobenzyl bromide (1.3 equiv) and 
NaH, using procedure G for 3 h, followed by chromatography of the product on silica gel, 
eluting with CH2Cl2 (foreruns) and then with 1% EtOAc/CH2Cl2, gave 33 (57%) as a white 
solid: mp (CH2Cl2/hexane) 157-159 C; 1H NMR (CDCl3)  7.46 (br d, J = 8.3 Hz, 2 H), 
7.39 (s, 1 H), 7.12 (br d, J = 8.3 Hz, 2 H), 4.50 (s, 2 H), 4.09 (ddd, J = 12.5, 6.9, 6.0 Hz, 1 
H), 4.01 (ddd, J = 12.5, 7.0, 6.0 Hz, 1 H), 3.62 (d, J = 10.2 Hz, 1 H), 3.58 (d, J = 10.2 Hz, 1 
H), 2.37 (ddd, J = 14.4, 7.0, 6.0 Hz, 1 H), 2.10 (ddd, J = 14.4, 6.9, 6.1 Hz, 1 H), 1.46 (s, 3 
H); [α]27D 31.0 (c 1.00, CHCl3); HRFABMS calcd for C15H17BrN3O4 m/z [M + H]+ 384.0382, 
382.0402, found 384.0385, 382.0398. 
(7R)-7-Methyl-2-nitro-7-({[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-
yl]methoxy}methyl)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (34). Reaction of 
bromide 33 with 4-(trifluoromethoxy)phenylboronic acid (1.5 equiv) and Pd(dppf)Cl2 (0.15 
equiv), using procedure H at 88 C for 75 min, followed by chromatography of the product 
on silica gel, eluting with 0-0.5% EtOAc/CH2Cl2 (foreruns) and then with 0.5-1.5% 
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EtOAc/CH2Cl2, gave 34 (90%) as a cream solid: mp (CH2Cl2/hexane) 165-167 C; 1H NMR 
(CDCl3)  7.58 (br d, J = 8.7 Hz, 2 H), 7.52 (br d, J = 8.2 Hz, 2 H), 7.38 (s, 1 H), 7.32 (br d, 
J = 8.1 Hz, 2 H), 7.28 (br d, J = 8.1 Hz, 2 H), 4.61 (d, J = 12.1 Hz, 1 H), 4.58 (d, J = 12.1 
Hz, 1 H), 4.11 (ddd, J = 12.4, 7.2, 5.8 Hz, 1 H), 4.01 (ddd, J = 12.6, 6.5, 6.1 Hz, 1 H), 3.67 
(d, J = 10.2 Hz, 1 H), 3.63 (d, J = 10.2 Hz, 1 H), 2.40 (ddd, J = 14.4, 6.6, 6.1 Hz, 1 H), 2.13 
(ddd, J = 14.5, 7.3, 6.0 Hz, 1 H), 1.48 (s, 3 H); [α]27D 37.0 (c 1.00, CHCl3). Anal. 
(C22H20F3N3O5) C, H, N. 
Synthesis of 44 (Scheme 2B): 
2-Chloro-1-(3-methylbut-3-en-1-yl)-4-nitro-1H-imidazole (41). Reaction of 2-chloro-4-
nitro-1H-imidazole (40) with 4-iodo-2-methylbut-1-ene26 (15) (1.1 equiv) and powdered 
K2CO3 (2.0 equiv), using procedure A for 14 h, gave 41 (84%) as a white solid: mp 
(CH2Cl2/petroleum ether) 70-72 C; 1H NMR (CDCl3)  7.72 (s, 1 H), 4.93-4.87 (m, 1 H), 
4.72-4.66 (m, 1 H), 4.13 (t, J = 7.1 Hz, 2 H), 2.52 (br t, J = 7.0 Hz, 2 H), 1.80 (br s, 3 H). 
Anal. (C8H10ClN3O2) C, H, N. 
2-Chloro-1-[2-(2-methyloxiran-2-yl)ethyl]-4-nitro-1H-imidazole (42). 3-
Chloroperoxybenzoic acid (14.4 g of 70%, 58.4 mmol) was added to a mixture of alkene 41 
(10.4 g, 48.2 mmol) and disodium hydrogen phosphate (10.4 g, 73.3 mmol) in CH2Cl2 (300 
mL) at 0 C. The mixture was stirred at 20 C for 4 h and then additional m-CPBA (2.40 g, 
9.74 mmol) and CH2Cl2 (50 mL) were added. The resulting mixture was stirred at 20 C for a 
further 14 h, and then cooled to -20 C and washed with an ice-cold aqueous solution of 
sodium sulphite (200 mL of 10%), back-extracting with CH2Cl2 (2 x 200 mL). The organic 
portions were sequentially washed with aqueous NaHCO3 (200 mL) and brine (100 mL), and 
then combined and concentrated under reduced pressure, and the remaining oil was 
chromatographed on silica gel. Elution with 3:1 CH2Cl2/petroleum ether first gave foreruns, 
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and then further elution with 3:1 CH2Cl2/petroleum ether and 0-2.5% EtOAc/CH2Cl2 gave 42 
(10.6 g, 95%) as a cream solid: mp (CH2Cl2/petroleum ether) 87-89 C; 1H NMR (CDCl3)  
7.79 (s, 1 H), 4.13 (t, J = 7.6 Hz, 2 H), 2.67 (br d, J = 4.4 Hz, 1 H), 2.62 (br d, J = 4.3 Hz, 1 
H), 2.19 (dt, J = 14.3, 7.7 Hz, 1 H), 2.04 (dt, J = 14.3, 7.4 Hz, 1 H), 1.40 (s, 3 H). Anal. 
(C8H10ClN3O3) C, H, N. 
Procedure J: 4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-2-methyl-1-[4-
(trifluoromethoxy)phenoxy]butan-2-ol (43). 4-(Trifluoromethoxy)phenol (0.280 mL, 2.16 
mmol) was added to a mixture of epoxide 42 (200 mg, 0.863 mmol) and powdered K2CO3 
(422 mg, 3.05 mmol) in anhydrous MEK (2.0 mL) under N2, and then the mixture was stirred 
at 82 C for 10 h. The resulting cooled mixture was diluted with water (50 mL) and extracted 
with CH2Cl2 (4 x 50 mL). The combined extracts were evaporated to dryness under reduced 
pressure (at 30 C) and the residue was chromatographed on silica gel. Elution with CH2Cl2 
first gave foreruns, and then further elution with 0-2% EtOAc/CH2Cl2 gave 43 (272 mg, 77%) 
as a pale yellow oil; 1H NMR (CDCl3)  7.81 (s, 1 H), 7.17 (br d, J = 9.1 Hz, 2 H), 6.90 (br d, 
J = 9.2 Hz, 2 H), 4.33-4.20 (m, 2 H), 3.85 (d, J = 9.0 Hz, 1 H), 3.82 (d, J = 9.0 Hz, 1 H), 
2.23 (ddd, J = 13.8, 9.3, 6.5 Hz, 1 H), 2.21 (s, 1 H), 2.04 (ddd, J = 13.8, 9.6, 6.6 Hz, 1 H), 
1.40 (s, 3 H); HRESIMS calcd for C15H16ClF3N3O5 m/z [M + H]
+ 412.0697, 410.0725, found 
412.0700, 410.0722. 
7-Methyl-2-nitro-7-{[4-(trifluoromethoxy)phenoxy]methyl}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (44). Reaction of alcohol 43 with NaH (1.7 equiv), using 
procedure D for 2 h, followed by chromatography of the product on silica gel, eluting with 
CH2Cl2, gave 44 (61%) as a cream solid: mp (CH2Cl2/pentane) 134-136 C; 1H NMR 
[(CD3)2SO]  8.10 (s, 1 H), 7.31 (br d, J = 9.0 Hz, 2 H), 7.07 (br d, J = 9.2 Hz, 2 H), 4.20 (s, 2 
H), 4.19 (dt, J = 13.3, 6.1 Hz, 1 H), 4.13 (ddd, J = 13.2, 8.1, 5.6 Hz, 1 H), 2.38 (ddd, J = 
32 
 
14.4, 7.9, 6.2 Hz, 1 H), 2.18 (dt, J = 14.4, 5.8 Hz, 1 H), 1.49 (s, 3 H); 13C NMR [(CD3)2SO]  
157.0, 147.2, 142.2, 142.1 (q, JC-F = 1.6 Hz), 122.5 (2 C), 120.1 (q, JC-F = 255.2 Hz), 117.7, 
115.9 (2 C), 80.4, 72.4, 39.5, 27.0, 21.3. Anal. (C15H14F3N3O5) C, H, N. 
Synthesis of 55 (Scheme 2A): 
Procedure K: 7-[(4-Iodophenoxy)methyl]-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (48). DEAD (0.270 mL, 1.74 mmol) was added dropwise to a stirred solution 
of alcohol 13 (251 mg, 1.26 mmol), 4-iodophenol (377 mg, 1.71 mmol), and PPh3 (448 mg, 
1.71 mmol) in anhydrous THF (3 mL) under N2 at 0 C. After being stirred at 20 C for 32 h, 
the mixture was concentrated under reduced pressure to give an oil, which was 
chromatographed on silica gel. Elution with CH2Cl2 first gave foreruns, and then further 
elution with 0-2% EtOAc/CH2Cl2 gave the crude product, which was further purified by 
chromatography on silica gel. Elution with 33-50% EtOAc/petroleum ether first gave 
foreruns, and then further elution with 10% MeOH/CH2Cl2 gave 48 (433 mg, 86%) as a cream 
solid: mp (MeOH/CH2Cl2/hexane) 224-227 C; 1H NMR [(CD3)2SO]  8.08 (s, 1 H), 7.62 (br 
d, J = 9.0 Hz, 2 H), 6.86 (br d, J = 9.0 Hz, 2 H), 4.94-4.85 (m, 1 H), 4.31 (dd, J = 11.1, 3.4 
Hz, 1 H), 4.25 (dd, J = 11.1, 5.8 Hz, 1 H), 4.18 (ddd, J = 12.6, 5.8, 3.0 Hz, 1 H), 4.09 (ddd, J 
= 12.5, 10.8, 5.2 Hz, 1 H), 2.35-2.26 (m, 1 H), 2.25-2.12 (m, 1 H). Anal. (C13H12IN3O4) C, H, 
N. 
Procedure L: 7-{[4-(6-Fluoropyridin-3-yl)phenoxy]methyl}-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (55). A stirred mixture of iodide 48 (70.3 mg, 0.175 mmol), (6-
fluoropyridin-3-yl)boronic acid (42.3 mg, 0.300 mmol), and Pd(dppf)Cl2 (19.5 mg, 0.0266 
mmol) in DMF (2.3 mL), toluene (1.5 mL), and EtOH (1.0 mL) was degassed for 8 min 
(vacuum pump) and then N2 was added. An aqueous solution of KHCO3 (0.40 mL of 2 M, 
0.80 mmol) was added by syringe and the stirred mixture was again degassed for 9 min, and 
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then N2 was added. The resulting mixture was stirred at 85 C for 2 h, and then cooled, 
diluted with aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (6 x 50 mL). The extracts 
were evaporated to dryness under reduced pressure (at 30 C) and the residue was 
chromatographed on silica gel. Elution with 0-4% EtOAc/CH2Cl2 first gave foreruns, and 
then further elution with 4-7% EtOAc/CH2Cl2 gave 55 (61 mg, 94%) as a cream solid: mp 
(MeOH/CH2Cl2/hexane) 197-198 C; 1H NMR [(CD3)2SO]  8.51 (br d, J = 2.6 Hz, 1 H), 
8.24 (td, J = 8.2, 2.6 Hz, 1 H), 8.10 (s, 1 H), 7.69 (br d, J = 8.8 Hz, 2 H), 7.24 (dd, J = 8.6, 
2.6 Hz, 1 H), 7.13 (br d, J = 8.8 Hz, 2 H), 4.99-4.88 (m, 1 H), 4.39 (dd, J = 11.1, 3.3 Hz, 1 
H), 4.33 (dd, J = 11.1, 5.8 Hz, 1 H), 4.20 (ddd, J = 12.5, 5.7, 2.9 Hz, 1 H), 4.11 (ddd, J = 
12.4, 10.9, 5.2 Hz, 1 H), 2.39-2.29 (m, 1 H), 2.29-2.15 (m, 1 H); 13C NMR [(CD3)2SO]  
162.2 (d, JC-F = 235.1 Hz), 158.2, 147.8, 144.8 (d, JC-F = 15.1 Hz), 142.1, 139.8 (d, JC-F = 8.0 
Hz), 133.7 (d, JC-F = 4.6 Hz), 128.7, 128.1 (2 C), 117.8, 115.3 (2 C), 109.5 (d, JC-F = 37.7 
Hz), 76.0, 68.8, 41.7, 22.4. Anal. (C18H15FN4O4) C, H, N. 
Synthesis of 59 (Scheme 2C): 
Procedure M: 7-{[(5-Bromopyridin-2-yl)oxy]methyl}-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (58). A mixture of alcohol 13 (500 mg, 2.51 mmol) and 5-
bromo-2-fluoropyridine (57) (0.52 mL, 5.05 mmol) in anhydrous DMF (10 mL) under N2 at 0 
C was treated with 60% NaH (151 mg, 3.78 mmol) and then quickly degassed and resealed 
under N2. Further 57 (0.52 mL, 5.05 mmol) was added and the mixture was stirred at 20 C 
for 2.5 h. The resulting mixture was cooled (CO2/acetone), quenched with ice/aqueous 
NaHCO3 (20 mL), and then added to brine (100 mL) and extracted with CH2Cl2 (8 x 100 
mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 C) 
and the residue was chromatographed on silica gel. Elution with 0-1% EtOAc/CH2Cl2 first 
gave foreruns, and then further elution with 2-4% EtOAc/CH2Cl2 gave 58 (778 mg, 87%) as a 
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white solid: mp (MeOH/CH2Cl2/hexane) 182-184 C; 1H NMR [(CD3)2SO]  8.30 (br d, J = 
2.6 Hz, 1 H), 8.07 (s, 1 H), 7.94 (dd, J = 8.8, 2.6 Hz, 1 H), 6.91 (br d, J = 8.8 Hz, 1 H), 4.95-
4.86 (m, 1 H), 4.58 (dd, J = 12.0, 3.3 Hz, 1 H), 4.52 (dd, J = 12.0, 6.0 Hz, 1 H), 4.17 (ddd, J 
= 12.6, 5.8, 2.8 Hz, 1 H), 4.09 (ddd, J = 12.5, 11.0, 5.2 Hz, 1 H), 2.35-2.25 (m, 1 H), 2.24-
2.10 (m, 1 H). Anal. (C12H11BrN4O4) C, H, N. 
Procedure N: 7-({[5-(4-Fluorophenyl)pyridin-2-yl]oxy}methyl)-2-nitro-6,7-dihydro-
5H-imidazo[2,1-b][1,3]oxazine (59). A stirred mixture of bromide 58 (150 mg, 0.422 
mmol), 4-fluorophenylboronic acid (117 mg, 0.836 mmol), and Pd(dppf)Cl2 (83.1 mg, 0.114 
mmol) in DMF (4.5 mL), toluene (3 mL), and EtOH (2 mL) was degassed for 10 min 
(vacuum pump) and then N2 was added. An aqueous solution of Na2CO3 (1.05 mL of 2 M, 
2.1 mmol) was added by syringe, the stirred mixture was again degassed for 10 min, and then 
N2 was added. The resulting mixture was stirred at 89 C for 2.5 h and then cooled, diluted 
with aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (6 x 50 mL). The combined 
extracts were evaporated to dryness under reduced pressure (at 30 C), and the residue was 
chromatographed on silica gel. Elution with 0-3% EtOAc/CH2Cl2 first gave foreruns, and 
then further elution with 3% EtOAc/CH2Cl2 gave 59 (143 mg, 91%) as a cream solid: mp 
(MeOH/CH2Cl2/hexane) 180-181 C; 1H NMR [(CD3)2SO]  8.47 (br d, J = 2.6 Hz, 1 H), 
8.09 (s, 1 H), 8.05 (dd, J = 8.6, 2.6 Hz, 1 H), 7.71 (br dd, J = 8.9, 5.4 Hz, 2 H), 7.30 (br t, J = 
8.9 Hz, 2 H), 6.98 (br d, J = 8.6 Hz, 1 H), 4.99-4.90 (m, 1 H), 4.64 (dd, J = 12.0, 3.4 Hz, 1 
H), 4.58 (dd, J = 12.0, 6.0 Hz, 1 H), 4.19 (ddd, J = 12.5, 5.8, 2.7 Hz, 1 H), 4.10 (ddd, J = 
12.5, 11.1, 5.1 Hz, 1 H), 2.38-2.28 (m, 1 H), 2.27-2.13 (m, 1 H); 13C NMR [(CD3)2SO]  
162.1, 161.9 (d, JC-F = 244.4 Hz), 147.8, 144.5, 142.0, 137.9, 133.3 (d, JC-F = 3.1 Hz), 128.9, 
128.4 (d, JC-F = 8.1 Hz, 2 C), 117.8, 115.8 (d, JC-F = 21.5 Hz, 2 C), 110.8, 76.0, 66.3, 41.7, 
22.5. Anal. (C18H15FN4O4) C, H, N. 
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Synthesis of 79 (Scheme 3B): 
2-Chloro-1-{2-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}-4-nitro-1H-imidazole (73). 
Reaction of 2-chloro-4-nitro-1H-imidazole (40) with (4R)-4-(2-iodoethyl)-2,2-dimethyl-1,3-
dioxolane33 (72) (0.96 equiv) and powdered K2CO3 (1.03 equiv), using procedure A for 3 d, 
followed by chromatography of the product on silica gel, eluting with 0-33% Et2O/petroleum 
ether (foreruns) and then with 33-50% Et2O/petroleum ether, gave 73 (74%) as a light yellow 
solid: mp (Et2O/pentane) 73-75 C; 1H NMR (CDCl3)  7.81 (s, 1 H), 4.23 (ddd, J = 14.2, 7.7, 
5.3 Hz, 1 H), 4.18 (ddd, J = 14.2, 8.0, 7.1 Hz, 1 H), 4.10 (dd, J = 7.9, 6.1 Hz, 1 H), 4.09-4.01 
(m, 1 H), 3.60 (dd, J = 7.8, 5.7 Hz, 1 H), 2.12-2.01 (m, 1 H), 2.01-1.90 (m, 1 H), 1.43 (s, 3 
H), 1.36 (s, 3 H); [α]26D 39.2 (c 1.020, CHCl3). Anal. (C10H14ClN3O4) C, H, N. 
Procedure O: (2R)-4-(2-Chloro-4-nitro-1H-imidazol-1-yl)butane-1,2-diol (74). Dilute 
HCl (13 mL of a 1 M solution, 13.0 mmol) was added dropwise to a stirred solution of acetonide 
73 (2.86 g, 10.4 mmol) in MeOH (39 mL) at 0 C. The mixture was stirred at 20 C for 6 h and 
then cooled in ice, treated with K2CO3 (0.90 g, 6.51 mmol), and stirred until the neutralisation 
was complete. Following filtration to remove inorganic material (washing with MeOH), the 
solvents were removed under reduced pressure (at 30 C), and the residue was 
chromatographed on silica gel. Elution with 0-67% EtOAc/petroleum ether first gave 
foreruns, and then further elution with EtOAc gave 74 (2.39 g, 98%) as a cream solid: mp 
(MeOH/CH2Cl2/hexane) 115-117 C; 1H NMR [(CD3)2SO]  8.55 (s, 1 H), 4.79 (d, J = 5.0 
Hz, 1 H), 4.60 (t, J = 5.6 Hz, 1 H), 4.21-4.08 (m, 2 H), 3.45-3.36 (m, 1 H), 3.36-3.29 (m, 1 
H), 3.22 (dt, J = 10.7, 5.9 Hz, 1 H), 2.03-1.91 (m, 1 H), 1.75-1.62 (m, 1 H); [α]24D 29.4 (c 
2.008, DMF). Anal. (C7H10ClN3O4) C, H, N. 
Procedure P: (2R)-4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-2-hydroxybutyl 4-
methylbenzenesulfonate (75). A solution of tosyl chloride (2.28 g, 12.0 mmol) in anhydrous 
pyridine (3 mL, then 2 x 1.5 mL to rinse) was added dropwise to a stirred solution of diol 74 
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(2.35 g, 9.97 mmol) in anhydrous pyridine (5 mL) under N2 at -10 C. The mixture was 
stirred at -10 to 0 C for 2 h and then at 20 C for 13 h. The resulting solution was cooled in 
ice and then added to ice-water (100 mL) and extracted with CH2Cl2 (4 x 100 mL). The 
combined extracts were concentrated to dryness under reduced pressure (at 30 C) and the 
remaining oil was chromatographed on silica gel. Elution with 0-2% EtOAc/CH2Cl2 first gave 
foreruns, and then further elution with 2-50% EtOAc/CH2Cl2 gave 75 (3.38 g, 87%) as a 
cream foam that was used directly in the next step; 1H NMR (CDCl3)  7.78 (s, 1 H), 7.78 (br 
d, J = 8.3 Hz, 2 H), 7.37 (br d, J = 8.0 Hz, 2 H), 4.22 (dd, J = 7.7, 6.0 Hz, 2 H), 4.04 (dd, J = 
10.5, 3.4 Hz, 1 H), 3.95 (dd, J = 10.5, 6.6 Hz, 1 H), 3.87-3.78 (m, 1 H), 2.62 (br d, J = 4.3 
Hz, 1 H), 2.47 (s, 3 H), 1.99-1.83 (m, 2 H); APCI MS m/z 392, 390 [M + H]+. 
Procedure Q: 2-Chloro-4-nitro-1-{2-[(2R)-oxiran-2-yl]ethyl}-1H-imidazole (76). 1,8-
Diazabicyclo[5.4.0]undec-7-ene (1.45 mL, 9.70 mmol) was added dropwise to a stirred 
solution of tosylate 75 (3.38 g, 8.67 mmol) in anhydrous CH2Cl2 (32 mL) under N2 at 0 C. 
The mixture was stirred at 0 C for 3 h, at 0-20 C for 2 h, and then at 20 C for 3 h. The 
resulting solution was added to a mixture of ice and brine (100 mL) and extracted with 
CH2Cl2 (4 x 100 mL). The combined extracts were concentrated to dryness under reduced 
pressure (at 30 C) and the remaining oil was chromatographed on silica gel. Elution with 
CH2Cl2 first gave foreruns, and then further elution with CH2Cl2 gave 76 (1.78 g, 94%) as a 
cream solid (after freezing): mp (CH2Cl2/pentane) 59-61 C; 1H NMR (CDCl3)  7.81 (s, 1 
H), 4.29-4.15 (m, 2 H), 2.99-2.91 (m, 1 H), 2.86 (dd, J = 4.7, 4.0 Hz, 1 H), 2.54 (dd, J = 4.8, 
2.6 Hz, 1 H), 2.36-2.25 (m, 1 H), 1.87-1.76 (m, 1 H); [α]25D 43.6 (c 1.009, CHCl3). Anal. 
(C7H8ClN3O3) C, H, N. 
Procedure R: (2R)-1-[(6-Bromopyridin-3-yl)oxy]-4-(2-chloro-4-nitro-1H-imidazol-1-
yl)butan-2-ol (77). A mixture of epoxide 76 (1.76 g, 8.07 mmol), 6-bromopyridin-3-ol (68) 
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(2.82 g, 16.2 mmol), and powdered K2CO3 (2.23 g, 16.1 mmol) in anhydrous MEK (21 mL) 
under N2 was stirred at 80-82 C for 42 h. The resulting cooled mixture was added to water 
(100 mL), washing in residues with MeOH/CH2Cl2, and then extracted with 10% 
MeOH/CH2Cl2 (3 x 100 mL) and 25% EtOAc/CH2Cl2 (3 x 100 mL). The combined extracts 
were concentrated to dryness under reduced pressure and the remaining oil was 
chromatographed on silica gel. Elution with 0-40% EtOAc/petroleum ether first gave 
foreruns, and then further elution with 50% EtOAc/petroleum ether gave 77 (1.71 g, 54%) as 
a cream solid: mp (MeOH/CH2Cl2/hexane) 134-135 C; 1H NMR [(CD3)2SO]  8.58 (s, 1 H), 
8.12 (d, J = 3.1 Hz, 1 H), 7.54 (d, J = 8.7 Hz, 1 H), 7.39 (dd, J = 8.8, 3.2 Hz, 1 H), 5.30 (d, J 
= 4.9 Hz, 1 H), 4.27-4.14 (m, 2 H), 3.99 (dd, J = 10.0, 4.8 Hz, 1 H), 3.95 (dd, J = 10.0, 5.5 
Hz, 1 H), 3.86-3.77 (m, 1 H), 2.11-2.00 (m, 1 H), 1.95-1.83 (m, 1 H); [α]24D 7.95 (c 1.006, 
DMF). Anal. (C12H12BrClN4O4) C, H, N. 
Further elution of the above column with 4:1 EtOAc/petroleum ether gave impurities and 
then elution with EtOAc gave crude oxazine 78 (0.46 g), which was chromatographed again 
on silica gel. Elution with 0-0.4% MeOH/CH2Cl2 first gave foreruns, and then elution with 
0.5% MeOH/CH2Cl2 gave purified 78 (305 mg, 11%) as a cream solid (see data below). 
(7R)-7-{[(6-Bromopyridin-3-yl)oxy]methyl}-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (78). Reaction of alcohol 77 with NaH (1.4 equiv), using procedure D (but 
extracting the product four times with 10% MeOH/CH2Cl2 and then four times with CH2Cl2), 
followed by chromatography of the product on silica gel, eluting with 0-0.5% MeOH/CH2Cl2 
(foreruns) and then with additional 0.5% MeOH/CH2Cl2, gave 78 (94%) as a cream solid: mp 
(MeOH/CH2Cl2/hexane) 211-212 C; 1H NMR [(CD3)2SO]  8.19 (d, J = 3.1 Hz, 1 H), 8.10 
(s, 1 H), 7.59 (br d, J = 8.7 Hz, 1 H), 7.47 (dd, J = 8.8, 3.2 Hz, 1 H), 4.96-4.89 (m, 1 H), 4.43 
(dd, J = 11.2, 3.2 Hz, 1 H), 4.37 (dd, J = 11.2, 5.8 Hz, 1 H), 4.18 (ddd, J = 12.5, 5.8, 2.9 Hz, 
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1 H), 4.09 (ddd, J = 12.5, 10.9, 5.2 Hz, 1 H), 2.35-2.26 (m, 1 H), 2.25-2.13 (m, 1 H); [α]24D -
61.9 (c 1.002, DMF). Anal. (C12H11BrN4O4) C, H, N. 
(7R)-7-({[6-(4-Fluorophenyl)pyridin-3-yl]oxy}methyl)-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (79). Reaction of bromide 78 with 4-fluorophenylboronic acid 
(1.9 equiv) and Pd(dppf)Cl2 (0.25 equiv), using procedure N at 87 C for 200 min (but 
extracting the product three times with 10% MeOH/CH2Cl2 and then three times with 
CH2Cl2), followed by chromatography of the product on silica gel, eluting with 0-0.5% 
MeOH/CH2Cl2 (foreruns) and then with 0.5-0.67% MeOH/CH2Cl2, gave 79 (87%) as a cream 
solid: mp (MeOH/CH2Cl2/hexane) 205-208 C; 1H NMR [(CD3)2SO]  8.43 (d, J = 2.9 Hz, 1 
H), 8.11 (s, 1 H), 8.07 (br dd, J = 8.9, 5.5 Hz, 2 H), 7.94 (d, J = 8.8 Hz, 1 H), 7.56 (dd, J = 
8.8, 3.0 Hz, 1 H), 7.28 (br t, J = 8.9 Hz, 2 H), 5.00-4.91 (m, 1 H), 4.47 (dd, J = 11.2, 3.2 Hz, 
1 H), 4.41 (dd, J = 11.2, 5.8 Hz, 1 H), 4.20 (ddd, J = 12.5, 5.7, 2.9 Hz, 1 H), 4.11 (ddd, J = 
12.4, 11.0, 5.2 Hz, 1 H), 2.39-2.29 (m, 1 H), 2.29-2.16 (m, 1 H); [α]23D -62.6 (c 1.006, DMF). 
Anal. (C18H15FN4O4) C, H, N. 
Compounds of Table 2. The following section details the syntheses of compounds 142 
and 160 of Table 2, via representative procedures and key intermediates, as described in 
Scheme 5. For the syntheses of all of the other compounds in Table 2, please refer to the 
Supporting Information. 
Synthesis of 142 (Scheme 5A): 
Procedure S: 4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-1-[4-(4-fluorophenyl)piperazin-1-
yl]butan-2-ol (141). A mixture of epoxide 67 (see the Supporting Information) (150 mg, 
0.689 mmol) and 1-(4-fluorophenyl)piperazine (140) (186 mg, 1.03 mmol) in MEK (3 mL) in 
a sealed vial was stirred at 70 C for 51 h. The resulting cooled mixture was transferred to a 
flask (in CH2Cl2) and evaporated to dryness under reduced pressure (at 30 C), and then the 
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residue was chromatographed on silica gel. Elution with 0-0.3% MeOH/CH2Cl2 first gave 
foreruns, and then further elution with 1-2% MeOH/CH2Cl2 gave 141 (225 mg, 82%) as a 
pale yellow oil; 1H NMR (CDCl3)  7.87 (s, 1 H), 6.97 (br dd, J = 9.2, 8.3 Hz, 2 H), 6.87 (br 
dd, J = 9.2, 4.6 Hz, 2 H), 4.27 (dd, J = 8.2, 5.7 Hz, 2 H), 3.67-3.58 (m, 1 H), 3.57 (v br s, 1 
H), 3.19-3.07 (m, 4 H), 2.85-2.77 (m, 2 H), 2.59-2.51 (m, 2 H), 2.41 (dd, J = 12.3, 4.0 Hz, 1 
H), 2.37 (dd, J = 12.3, 9.5 Hz, 1 H), 1.98-1.87 (m, 1 H), 1.82-1.70 (m, 1 H); HRESIMS calcd 
for C17H22ClFN5O3 m/z [M + H]
+ 400.1366, 398.1390, found 400.1370, 398.1397. 
7-{[4-(4-Fluorophenyl)piperazin-1-yl]methyl}-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (142). Reaction of alcohol 141 with NaH, using procedure D at 40 C for 2 h, 
followed by chromatography of the product on silica gel, eluting with 0-0.5% MeOH/CH2Cl2 
(foreruns) and then with 1% MeOH/CH2Cl2, gave 142 (67%) as a pale yellow solid: mp 
(CH2Cl2/hexane) 213-215 C; 1H NMR [(CD3)2SO]  8.07 (s, 1 H), 7.04 (br dd, J = 9.2, 8.6 
Hz, 2 H), 6.94 (br dd, J = 9.3, 4.7 Hz, 2 H), 4.79-4.68 (m, 1 H), 4.13 (ddd, J = 12.6, 5.9, 2.9 
Hz, 1 H), 4.05 (ddd, J = 12.5, 10.8, 5.1 Hz, 1 H), 3.13-3.03 (m, 4 H), 2.73 (dd, J = 13.5, 6.6 
Hz, 1 H), 2.70-2.60 (m, 5 H), 2.29-2.19 (m, 1 H), 2.09-1.95 (m, 1 H); 13C NMR [(CD3)2SO]  
156.0 (d, JC-F = 235.6 Hz), 148.0, 147.9 (d, JC-F = 1.6 Hz), 142.1, 117.7, 117.1 (d, JC-F = 7.6 
Hz, 2 C), 115.2 (d, JC-F = 21.7 Hz, 2 C), 76.0, 60.5, 53.2 (2 C), 49.0 (2 C), 41.8, 24.3. Anal. 
(C17H20FN5O3) C, H, N. 
Synthesis of 160 (Scheme 5C): 
Procedure T: (2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl 4-(4-
fluorophenyl)piperazine-1-carboxylate (160). Triphosgene (145 mg, 0.489 mmol) was 
added to a mixture of alcohol 13 (192 mg, 0.964 mmol) and triethylamine (0.40 mL, 2.87 
mmol) in anhydrous THF (15 mL). The mixture was stirred at 20 C for 30 min and then a 
solution of 1-(4-fluorophenyl)piperazine (140) (347 mg, 1.93 mmol) in anhydrous THF (5 
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mL) was added. The resulting mixture was stirred at 20 C for 2 h and then quenched with 
saturated NH4Cl (100 mL) and extracted with EtOAc (2 x 100 mL). The combined extracts 
were evaporated to dryness under reduced pressure and the residue was chromatographed on 
silica gel. Elution with 0-2% MeOH/CH2Cl2 gave crude material, which was successively 
recrystallized from CH2Cl2/hexane and EtOAc/hexane, to give 160 (130 mg, 33%) as a cream 
solid: mp 177-180 C; 1H NMR [(CD3)2SO]  8.08 (s, 1 H), 7.06 (br dd, J = 9.1, 8.7 Hz, 2 H), 
6.97 (br dd, J = 9.2, 4.7 Hz, 2 H), 4.84-4.73 (m, 1 H), 4.37 (dd, J = 12.2, 3.2 Hz, 1 H), 4.29 
(dd, J = 12.2, 5.8 Hz, 1 H), 4.15 (ddd, J = 12.5, 5.8, 2.7 Hz, 1 H), 4.06 (ddd, J = 12.4, 11.3, 
5.1 Hz, 1 H), 3.61-3.45 (m, 4 H), 3.14-2.98 (m, 4 H), 2.30-2.20 (m, 1 H), 2.17-2.03 (m, 1 H); 
13C NMR [(CD3)2SO]  156.3 (d, JC-F = 236.3 Hz), 154.1, 147.8, 147.7 (d, JC-F = 1.6 Hz), 
142.0, 117.9 (d, JC-F = 7.5 Hz, 2 C), 117.7, 115.3 (d, JC-F = 22.0 Hz, 2 C), 75.8, 65.5, 49.1 (2 
C), 43.4 (2 C), 41.7, 22.3. Anal. (C18H20FN5O5) C, H, N. 
Minimum Inhibitory Concentration Assays (MABA and LORA). These were carried 
out according to the published protocols.41,56 
In Vitro Parasite Growth Inhibition Assays. The activity of test compounds against the 
amastigote stage of the L. don parasite was assessed at CDRI using a mouse macrophage-
based luciferase assay, performed according to the reported procedures.10 Further assays 
measuring the growth inhibitory action of compounds against L. inf, T. cruzi, and T. brucei, 
and determining any cytotoxic effects on human lung fibroblasts (MRC-5 cells), were 
conducted at the University of Antwerp (LMPH), as detailed in a recent article.40 
Solubility Determinations. Method A. The solid compound sample was mixed with water 
or 0.1 M HCl (enough to make a 2 mM solution) in an Eppendorf tube, and the suspension 
was sonicated for 15 min and then centrifuged at 13000 rpm for 6 min. An aliquot of the clear 
supernatant was diluted 2-fold with water (or 0.1 M HCl), and then HPLC was conducted. 
The kinetic solubility was calculated by comparing the peak area obtained with that from a 
41 
 
standard solution of the compound in DMSO (after allowing for varying dilution factors and 
injection volumes). 
Method B. The thermodynamic solubility of compound 4 at pH 7.4 was measured by 
Drugabilis, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France. The dry powder 
was stirred with 0.12 M phosphate buffer (pH 7.4) at 20 C for 24 h. After filtration using a 
0.22 μm PVDF membrane filter, the concentration of 4 was determined by HPLC with 
reference to a standard solution; the final value is the mean from two independent assays. 
Method C. The thermodynamic solubility of compound 79 at pH 6.5 and 5.0 was measured 
by WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, 
Shanghai 200131, China. Aliquots of the compound DMSO stock (10 mM) were transferred 
to fasted state simulated intestinal fluid buffer (pH 6.5) or fed state simulated intestinal fluid 
buffer (pH 5.0) and the mixtures were shaken for 24 h at room temperature. Following 
sampling by a Whatman filter device, the compound concentrations were determined by UV 
spectroscopy with reference to three calibration standards (2, 100, and 200 μM). 
Method D. The thermodynamic solubility of compound 79 at pH 7.4 was measured by 
Syngene International Ltd., Plot No. 2 & 3 Biocon Park, Jigani Link Rd, Bangalore 560099, 
India. The dry powder was equilibrated with 0.1 M phosphate buffer (pH 7.4) in a glass vial 
at 25 C (water bath), shaking for 24 h. After filtration using a 0.45 μm PVDF membrane 
filter, the concentration of 79 was determined by HPLC, comparing the peak area obtained 
with that from a standard solution (0.86 μM) in 1:1:2 EtOH/water/CH3CN. 
Microsomal Stability Assays. Tests on initial compounds 14, 29, 34, 38, and 39 (Table 3) 
were run by MDS Pharma Services, 22011 30th Drive SE, Bothell, WA 98021-4444, as 
previously described.58 Compounds 39, 44, 49, 53, 54, 59, 61, 71, 107, 108, 111-113, and 116 
were evaluated by Advinus Therapeutics Ltd., 21 & 22 Phase II, Peenya Industrial Area, 
Bangalore 560058, India, using a published procedure54 in which the compound 
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concentration was 0.5 µM and the incubation time was 30 min. Additional analyses on 
compounds 28, 44, 59, 62, 71, 79, 87, 90, 91, 93-95, 129, 142, 152, 170, and 178 were 
performed by WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe ZhongLu, WaiGaoQiao Free 
Trade Zone, Shanghai 200131, China, via a reported method.11 
Distribution Coefficient and pKa Measurements. The octanol-water partition coefficient 
(LogP) of 4 at 20 °C was measured in duplicate by Advinus Therapeutics Ltd., Bangalore, 
India, using the shake-flask method with HPLC analysis. LogD and pKa data for 79 were 
measured by WuXi AppTec (Shanghai) Co., Ltd. The LogD value was found by assessing the 
distribution of 79 between 100 mM phosphate buffer of pH 7.4 and octanol at room 
temperature (final matrix contained 1% DMSO), using the shake-flask method and LC-
MS/MS analysis. The pKa value was obtained by UV spectroscopy, employing 80% MeOH 
as the initial cosolvent. 
Plasma Protein Binding Assay. Studies of 4 and 79 were conducted by WuXi AppTec 
(Shanghai) Co., Ltd., using equilibrium dialysis across a semi-permeable membrane. Briefly, 
a 2 μM compound solution in plasma (0.5% DMSO) was dialyzed against 100 mM phosphate 
buffered saline (pH 7.4) on a rotating plate incubated for 4 or 6 h at 37 C. Following 
precipitation of protein with CH3CN, the amount of compound present in each compartment 
was quantified by LC-MS/MS; values are the mean of triplicate determinations. 
Permeability Assay. This was performed by WuXi AppTec (Shanghai) Co., Ltd. MDCK-
MDR1 cells were seeded onto polyethylene membranes in 96-well plates at 2 x 105 cells/cm2, 
giving confluent cell monolayer formation over 4-7 d. A solution of 79 (2 µM in 0.4% 
DMSO/HBSS buffer) was applied to the apical or basolateral side of the cell monolayer. 
Permeation of the compound from A to B direction or B to A direction was determined in 
triplicate over a 150 min incubation at 37 °C and 5% CO2 (95% humidity). In addition, the 
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efflux ratio of 79 was also determined. Test and reference compounds were quantified by LC-
MS/MS analysis based on the peak area ratio of analyte/internal standard. 
Ames Test. Compound 71 (at doses of 1.5, 4, 10, 25, 64, 160, 400, and 1000 µg/well) was 
evaluated in the Mini-Ames reverse mutation screen conducted by WuXi AppTec (Suzhou) 
Co., Ltd., 1318 Wuzhong Avenue, Wuzhong District, Suzhou 215104, China. Two 
Salmonella strains (TA98 and TA100) were employed, both in the presence and absence of 
metabolic activation (rat liver S9). Positive controls (2-aminoanthracene, 2-nitrofluorene and 
sodium azide) and a negative (DMSO solvent) control were included. 
hERG Assay. The effects of compounds 44 and 79 on cloned hERG potassium channels 
expressed in Chinese hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co., 
Ltd., using the automated patch clamp method. Six concentrations (0.12, 0.37, 1.11, 3.33, 10, 
and 30 µM) were tested (at room temperature) and at least three replicates were obtained for 
each. 
CYP3A4 Inhibition Assay. The study was performed by WuXi AppTec (Shanghai) Co., 
Ltd. Compound 79 (at concentrations of 1 and 10 µM) was incubated with NADPH-fortified 
pooled HLM (0.2 mg/mL) and testosterone (50 µM) in phosphate buffer (100 mM) at 37 C 
for 10 min. Following quenching with CH3CN, samples were analysed for the formation of 
6β-hydroxytestosterone by LC-MS/MS and the percentage inhibition was determined 
(ketoconazole was the positive control and tolbutamide was used as an internal standard). 
In Vivo Experiments. All animal experiments were performed according to institutional 
ethical guidelines for animal care. Antitubercular efficacy studies in mice were approved by 
the UIC IACUC (UIC AWA no. A3460-01; ACC application no. 12-183). For VL, mouse 
model studies (LSHTM) were conducted under license from the UK Home Office (license 
no. PIL 70/6997), hamster studies at CDRI were approved by the CSIR-CDRI animal ethics 
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committee (license no. 19/2009/PARA/IAEC), and hamster studies at LMPH were approved 
by the ethical committee of the University of Antwerp (UA-ECD 2010-17). 
Acute TB Infection Assay. Each compound (including 6, which was employed as an 
internal reference standard) was administered orally to a group of 7 M. tb-infected BALB/c 
mice at 100 mg/kg daily for 5 days a week for 3 weeks, beginning on day 11 postinfection, in 
accordance with published protocols.41,58 The results were typically recorded as the ratio of 
the average reduction in colony forming units (CFUs) in the compound-treated mice/the 
average CFU reduction in the mice treated with 6. 
Acute VL Infection Assay (Mouse Model, LSHTM). Test compounds were orally dosed 
once per day for 5 days consecutively to groups of 5 female BALB/c mice infected with 2 x 
107 L. donovani amastigotes, with treatment commencing one week postinfection, as 
described.10 Miltefosine (1) and AmBisome were positive controls, and parasite burdens were 
determined from impression smears of liver sections. Efficacy was expressed as the mean 
percentage reduction in parasite load for treated mice in comparison to untreated (vehicle-
only) controls. 
Chronic VL Infection Assay 1 (Hamster Model, CDRI). Golden hamsters (weighing 40-
45 g) were infected intracardially with 1 x 107 L. donovani amastigotes, and then, 15 days 
later, all animals were subjected to splenic biopsy to assess the level of infection. Groups of 
hamsters having an appropriate infection grading (5-15 amastigotes/100 spleen cell nuclei) 
were treated with test compounds, starting on day 17 and dosing orally once per day for 5 
days, according to the usual procedure.10 Post-treatment splenic biopsies taken 12 days after 
the first dose were employed to determine the intensity of infection, as previously reported.10 
Chronic VL Infection Assay 2 (Hamster Model, LMPH). Golden hamsters (weighing 
75-80 g) were infected with 2 x 107 L. infantum amastigotes, and 21 days post-infection, 
treatment groups of 6 animals each were dosed orally once or twice per day with test 
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compounds (formulated in PEG-400) for 5 days consecutively. Parasite burdens in three 
target organs (liver, spleen, and bone marrow) were determined by microscopic evaluation of 
impression smears (stained with Giemsa), and efficacy was expressed as the mean percentage 
load reduction for treated hamsters in comparison to untreated (vehicle-only) controls. 
Miltefosine (1) was included as a reference drug in all experiments. 
Mouse Pharmacokinetics. Compound 28 was evaluated by UNT Health Science Center, 
3500 Camp Bowie Boulevard, Fort Worth, TX 76107-2699 (using a method approved by the 
UNTHSC IACUC; AWA no. A3711-01). Following oral administration to female BALB/c 
mice at 40 mg/kg as a suspension in 0.5% carboxymethylcellulose/water, blood samples were 
collected (at time intervals of 0.5, 1, 1.5, 2, 4, 6, 8, and 24 h), centrifuged, and analyzed by 
LC-MS/MS to generate the required PK parameters. Compound 34 was assessed by MDS 
Pharma Services, 22002 26th Avenue SE, Suite 104, Bothell, WA 98021-4444, via a similar 
procedure (but employing mixed gender CD-1 mice and an oral formulation of 0.5% 
carboxymethylcellulose and 0.08% Tween 80 in water). Studies of compounds 39, 44, 49, 53, 
54, and 112 were conducted by Advinus Therapeutics Ltd., 21 and 22 Phase II, Peenya 
Industrial Area, Bangalore 560058, India, according to a published protocol.54 Briefly, 
compounds were administered to groups of male Swiss Albino mice; intravenous dosing (at 1 
mg/kg) employed a solution vehicle comprising 20% NMP and 40% PEG-400 in 100mM 
citrate buffer, pH 3, while oral dosing (at 25 mg/kg) was as a suspension in 0.5% 
carboxymethylcellulose and 0.08% Tween 80 in water (except for 112, where the iv solution 
was 10% NMP, 10% cremophor EL and 10% propylene glycol in saline, and oral dosing at 
12.5 mg/kg was as a suspension in 7% Tween 80 and 3% EtOH in water). Samples derived 
from plasma (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24 and 48 h) were centrifuged 
prior to analysis by LC-MS/MS and the PK parameters were determined using WinNonlin 
software (version 5.2). Finally, 71 was examined by WuXi AppTec (Shanghai) Co., Ltd.; in 
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this case, oral dosing of female BALB/c mice was at 25 mg/kg in PEG-400 (sampling at 0.25, 
1, 2, 4, 8, and 24 h), and the PK data were derived following similar LC-MS/MS analysis. 
Rat and Hamster Pharmacokinetics. Compounds 71, 79, and 87 were assessed in male 
Sprague-Dawley rats and female Golden Syrian hamsters by WuXi AppTec (Shanghai) Co., 
Ltd. Intravenous dosing (at 1 mg/kg for rats and 2 mg/kg for hamsters) utilised a solution 
formulation of 20% NMP and 40% PEG-400 in citrate buffer, pH 3. In rats, oral dosing (at 5 
mg/kg) was as a suspension in 0.08% Tween 80 and 0.5% carboxymethylcellulose in water, 
whereas PEG-400 was the vehicle employed for oral dosing in hamsters (at 12.5 mg/kg). 
Plasma samples (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 8, and 24 h) were analysed by LC-
MS/MS and the PK parameters were calculated using WinNonlin software (version 6.3). 
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Table 1. In vitro antiparasitic and antitubercular activities and calculated lipophilicities of 7-
substituted 2-nitroimidazooxazines 
 
      IC50
a,b (µM) MICc,b (µM) 
 compd Fm X aza R CLogP L. don L. inf T. cruzi MRC-5 MABA LORA 
4d     3.47 0.03 0.17 2.6 >64 0.046 5.9 
14 A H  4-OCF3 3.30 0.03 0.12 1.2 >64 1.0 7.5 
21 A Me  4-OCF3 3.68 0.31 0.30 0.75 >64 0.55 3.3 
22 A H  4-OBn 3.55 0.05    0.46 3.0 
23 A Me  4-OBn 3.93 0.28    0.20 1.4 
25 B H  4-F 4.21 0.02 0.17 0.53 >64 0.08 1.3 
27 B Me  4-F 4.59 0.22 1.8 0.84 >64 0.085 0.61 
28 B H  4-OCF3 5.14 0.19 0.40 2.1 >64 0.055 1.5 
29 B Me  4-OCF3 5.52 1.1 1.1 0.54 >64 0.093 1.4 
34 Be Me  4-OCF3 5.52 0.24 1.3 0.57 >64 0.063 1.1 
38 Bf Me  4-OCF3 5.52 1.3 1.3 0.77 >64 0.74 6.8 
39 C H  4-OCF3 3.37 0.04 0.047 0.061 >64 5.2 4.7 
44 C Me  4-OCF3 3.75 0.10 0.13 0.14 >64 0.94 6.8 
45 C H  4-OBn 3.62 0.02    >128 >128 
47 C Me  4-OBn 4.00 0.12    0.44 >128 
49 D H  4-F 4.11 0.01 0.47 0.063 >64 0.18 >128 
52 D Me  4-F 4.49 0.20 0.34 0.35 >64 0.085 1.4 
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53 D H  4-OCF3 5.03 0.06 0.28 0.24 >64 0.08 0.73 
54 D Me  4-OCF3 5.41 0.52 0.36 0.72 >64 0.11 1.3 
Phenylpyridines 
55 D H 3 4-F 2.94 >10 0.083 0.027 >64 0.24 3.5 
56 D Me 3 4-F 3.32 0.12 0.16 0.30 >64 0.29 2.7 
59 D H 2’ 4-F 3.66 0.01 0.050 0.027 >64 0.025 <0.25 
61 D Me 2’ 4-F 4.04 0.09 0.097 0.23 >64 0.17 1.0 
62 D H 2’ 2,4-diF 3.65 0.07 0.037 0.030 >64 0.10 2.4 
63 D Me 2’ 2,4-diF 4.03  0.11 0.21 >64 0.089 2.5 
64 D H 2’ 4-OCF3 4.58 0.05 0.35 0.12 >64 0.027 0.47 
65 D Me 2’ 4-OCF3 4.96 0.26 3.8 1.0 >64 0.13 5.3 
71 D H 3’ 4-F 3.03 0.06 0.093 0.27 >64 0.23 2.4 
79 De H 3’ 4-F 3.03 (0.03)g 0.080 0.35 >64 0.11 3.2 
87 Df H 3’ 4-F 3.03 (0.08)g 0.22 0.29 >64 1.1 3.9 
90 D Me 3’ 4-F 3.41 0.65 0.59 0.26 >64 0.35 3.9 
91 D H 3’ 2,4-diF 3.03 0.02 0.030 0.13 >64 0.36 8.9 
92 D Me 3’ 2,4-diF 3.41 0.31 0.17 0.27 >64 0.40 4.9 
93 D H 3’ 4-OCF3 3.96 0.05 0.12 0.17 >64 0.032 0.86 
94 De H 3’ 4-OCF3 3.96  0.11 0.26 >64 0.024 1.5 
95 Df H 3’ 4-OCF3 3.96  0.13 0.13 >64 0.34 1.6 
96 D Me 3’ 4-OCF3 4.34 0.65 4.0 0.25 >64 0.05 0.88 
99 E H 2’ 4-F 3.55 0.31 0.14 0.16 59 1.7 3.0 
101 E Me 2’ 4-F 3.93  0.18 0.35 >64 0.94 5.0 
102 E H 2’ 2,4-diF 3.55 0.25 4.0 0.23 >64 >128 >128 
103 E Me 2’ 2,4-diF 3.93  0.24 0.22 >64 0.69 4.8 
Bipyridines 
105 D H 2’,2 4-F 2.55 0.06 50 0.34 >64 0.15 11 
106 D Me 2’,2 4-F 2.93 0.15 0.34 0.25 >64 0.40 9.5 
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107 D H 2’,3 4-F 2.49 0.27 47 0.54 >64 0.074 15 
108 D Me 2’,3 4-F 2.87 0.22 0.40 0.82 >64 1.9 6.2 
109 D H 2’,3 2,4-diF 2.60 >10 0.19 0.29 >64 0.25 4.2 
110 D Me 2’,3 2,4-diF 2.98  0.20 0.43 >64 1.0 6.6 
111 D H 2’,3 4-CF3 2.89 0.13 2.5 0.68 >64 0.09 2.5 
112 D H 3’,3 4-F 1.87 0.09 >64 0.55 >64 2.3 21 
113 D Me 3’,3 4-F 2.25 0.09 0.67 0.57 >64 2.7 43 
114 D H 3’,3 2,4-diF 1.98 0.08 52 0.35 >64 1.2 41 
115 D Me 3’,3 2,4-diF 2.36 0.11 0.28 0.38 >64 0.94 18 
116 D H 3’,3 4-CF3 2.61 0.07 7.3 0.46 >64 0.12 58 
117 E H 2’,3 4-F 2.38 >10 44 0.13 35 >128 >128 
118 E Me 2’,3 4-F 2.76  1.1 0.52 >64 11 7.8 
119 E H 2’,3 2,4-diF 2.50 0.25 6.7 0.13 >64 4.3 10 
120 E Me 2’,3 2,4-diF 2.88  0.59 0.49 >64 9.3 7.9 
Other heterobiaryls 
123 D H 2’,3’ 4-F 2.73 0.07 8.4 0.67 >64 0.35 23 
126 D H 2’,5’ 4-F 3.09 0.15 0.71 4.7 >64 0.15 >128 
129 D H 2’,6’ 4-F 2.58 0.10 0.29 0.17 >64 0.04 1.7 
131 D Me 2’,6’ 4-F 2.96 0.32 0.29 0.43 57 0.44 6.3 
132 D H 2’,6’,3 4-F 1.41 0.53 >64 3.3 >64 0.24 21 
133 D Me 2’,6’,3 4-F 1.79 1.3 6.1 2.9 >64 23 54 
139 D H 3’,5’ 4-F 2.79 0.07 0.21 0.26 62 0.27 20 
aIC50 values for inhibition of the growth of Leishmania donovani and Leishmania infantum 
(in mouse macrophages) and Trypanosoma cruzi (on MRC-5 cells), or for cytotoxicity 
toward human lung fibroblasts (MRC-5 cells). bEach value (except the single test L. don data) 
is the mean of at least two independent determinations. For complete results (mean  SD) 
please refer to the Supporting Information. cMinimum inhibitory concentration against M. tb, 
determined under aerobic (MABA)41 or hypoxic (LORA)56 conditions. dData from reference 
11. e(R)-Enantiomer. f(S)-Enantiomer. gLMPH data (mean of 2 values).  
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Table 2. In vitro antiparasitic and antitubercular activities and calculated lipophilicities of 
cyclic amine-based analogues 
 
    IC50
a,b (µM) MICc,b (µM) 
compd Fm X CLogP L. don L. inf T. cruzi MRC-5 MABA LORA 
142 A H 2.16 0.19 2.3 1.7 >64 1.8 9.9 
144 A Me 2.54 0.70 0.73 1.3 >64 0.34 6.8 
147 B H 3.36 0.88 0.87 2.9 >64 2.1 11 
149 B Me 3.74 1.0 0.32 0.87 >64 0.22 8.3 
152 C H 2.84 0.45 0.84 2.4 >64 2.0 22 
154 C Me 3.22 0.22 0.32 0.59 >64 0.23 48 
157 D H 1.17 4.8 45 11 >64 46 >128 
159 D Me 1.55 2.8 6.5 2.8 >64 93 >128 
160 E H 2.42 >100 >64 1.5 >64 2.5 22 
161 E Me 2.80 0.29 0.72 3.9 >64 3.4 8.4 
170 F H 3.50  0.24 0.22 >64 0.78 20 
178 F Me 3.88  0.35 0.51 >64 0.37 19 
aIC50 values for inhibition of the growth of Leishmania donovani and Leishmania infantum 
(in mouse macrophages) and Trypanosoma cruzi (on MRC-5 cells), or for cytotoxicity 
toward human lung fibroblasts (MRC-5 cells). bEach value (except the single test L. don data) 
is the mean of at least two independent determinations. For complete results (mean  SD) 
please refer to the Supporting Information. cMinimum inhibitory concentration against M. tb, 
determined under aerobic (MABA)41 or hypoxic (LORA)56 conditions.  
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Table 3. Aqueous solubility, microsomal stability, and in vivo antileishmanial efficacy data 
for selected analogues 
 aq solubilitya 
(µg/mL) 
microsomal stabilityb 
[% remaining at 1 (0.5) h] 
in vivo efficacy against L. don (mouse) 
(% inhibition at dose in mg/kg)c 
compd pH 7 pH 1 H M Ham 50 25 12.5 6.25 3.13 1.56 
4d 2.4  (92) (89) 18 (54)   >99 >99 83 49 
14 4.8  57 10        
28 0.058  73 75 46 49      
29 0.39  85 77        
34   86 79        
38   86 59        
39 4.0  85 (96) 57 (70) (23)  87     
44 2.3  58 (86) 50 (61) 2.1 (16)  100 100 83 25  
49 0.055  (88) (75) (45)  >99     
53 0.13  (97) (94) (94)  65     
54 2.6  (89) (85) (81)  30     
55 0.36           
59 0.13 2.8 41 43 (60) 12 (16) 67      
61 0.69 13  (33) (2.6)       
62 0.13 1.5 25 19 2.7       
71 0.32 164 44 34 (63) 14 (52) 100 98 76 59   
79 0.45 237 58 69 34    93   
87 0.47 234 63 41 5    85   
90 0.19 74 50 28 32 41      
91 0.72 221 45 31 8.6 91      
93 0.15 92 53 41 37 >99   >99 97 50 
94 0.37 110 50 53      >99 84 
95 0.40 141 52 46      52 57 
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99 0.027 0.56          
107 0.87   (81) (51)       
108 4.5   (68) (39)       
111 0.36   (72) (70)       
112 3.9  (93) (87) (70) 44      
113 2.3   (82) (43)       
116 0.30   (82) (81)       
129 1.8  61 56 13 85      
139 0.59           
142 10 14900 85 77 15 55      
152 49 21100 57 58 0       
170 6.1 34300 33 17 0.7 45      
178 2.2 9970 11 1.2 0.2       
aKinetic solubility (µg/mL) in water (pH 7) or 0.1 M HCl (pH 1) at 20 °C, determined by 
HPLC (see the Experimental Section, Method A). bPooled human (H), CD-1 mouse (M), or 
hamster (Ham) liver microsomes; data in parentheses are the percentage parent compound 
remaining following a 30 min incubation. cDosing was orally, once daily for 5 days 
consecutively; data are the mean percentage reduction of parasite burden in the liver. dData 
from reference 11.  
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Table 4. Pharmacokinetic parameters for selected compounds in various species 
 
compd 
intravenous (1-2 mg/kg)a  oral (5-40 mg/kg)a 
C0 
(µg/mL) 
CL 
(mL/ 
min/kg) 
Vdss 
(L/kg) 
t1/2 
(h) 
AUClast
b 
(µgh/mL) 
 
Cmax 
(µg/mL) 
Tmax 
(h) 
t1/2 
(h) 
AUClast
b 
(µgh/mL) 
Fc 
(%) 
Mice 
Rac-4d 0.88 9.5 1.7 2.2 1.69  4.1 4.0  33.5 79 
28       3.3 8.0 5.2 47.1e  
34       2.0 6.0 8.1 31.9e  
39 0.36 48 3.2 1.1 0.341  1.3 0.5  3.86 45 
44 0.79 12 2.5 2.8 1.31  1.4 3.0  11.5 35 
49 2.9 0.52 0.40 6.7 31.6  4.2 6.0  84.7 11 
53 0.66 1.3 1.9 17 11.2  14 8.0  376 100 
54 0.43 2.3 5.0 27 5.26  0.79 10  22.7 17 
71       13 4.0 3.4 112  
112 14 0.70 0.12 2.1 24.7  14 2.0  95.3 31 
Rats 
71 1.3 3.9 0.94 3.0 4.36  0.49 3.3 6.7 4.27 22 
79 1.5 6.3 0.86 1.7 2.65  0.79 3.3 3.1 4.08 34 
87 1.1 5.5 1.4 3.2 3.14  0.71 3.3 3.7 5.64 41 
Hamsters 
71 2.5 11 1.0 1.2 3.12  0.94 2.7 4.7 4.83 26 
79       1.4 2.0 4.2 6.82  
87       0.73 2.7 10 3.68  
aThe intravenous dose was 1 mg/kg for mice and rats and 2 mg/kg for hamsters. The oral 
dose in mice was 25 mg/kg, except for 28 and 34 (40 mg/kg) and 112 (12.5 mg/kg); in other 
species, the oral doses were 5 mg/kg (rats) or 12.5 mg/kg (hamsters). bArea under the curve 
calculated to the last time point (10, 24, or 48 h). cOral bioavailability, determined using dose 
normalised AUClast values. 
dData for racemic 4 from reference 11. eExtrapolated AUCinf 
value.  
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Table 5. In vivo efficacy data for selected lead compounds in the L. inf hamster model 
 
compd 
 
dose regimena 
% inhibition in target organsb 
liver spleen bone marrow 
1 40 mg/kg, q.d. 92.6 99.5 89.0 
4c 25 mg/kg, q.d. 100 99.9 99.7 
 12.5 mg/kg, q.d. 99.0 98.7 94.0 
44 25 mg/kg, b.i.d. 92.2 91.1 82.5 
 50 mg/kg, q.d. 88.6 89.5 73.0 
71 25 mg/kg, b.i.d. 99.9 99.4 99.6 
 12.5 mg/kg, b.i.d. 99.9 99.5 99.4 
 6.25 mg/kg, b.i.d. 98.0 95.7 96.3 
 3.13 mg/kg, b.i.d. 68.3 69.8 64.5 
 12.5 mg/kg, q.d. 95.2 87.5 92.8 
79 12.5 mg/kg, b.i.d. 99.5 99.4 96.8 
 6.25 mg/kg, b.i.d. 91.0 91.6 73.3 
87 12.5 mg/kg, b.i.d. 88.2 80.8 82.3 
 6.25 mg/kg, b.i.d. 53.1 46.7 35.0 
aAll compounds were dosed orally, once or twice daily for 5 days consecutively. bData are 
the mean percentage reduction of parasite burden in target organs. cData from reference 11.  
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Table 6. Additional comparative data for lead compounds 4 and 79 
property 4 79 
Molecular weight (Da) 359.3 370.3 
LogD (measured) 3.10 2.45a 
pKa (measured)  3.95
a 
Thermodynamic solubility (µM): 
pH 7.4 
pH 6.5/5.0 
 
2.8 
 
5.4b 
3.1/18 
Permeability:  
Papp (x10
-6 cm/s) A to B/B to A 
 
22.6/24.7c 
 
29.2/26.2d 
Human plasma protein binding (%) 93.9 96.5 
Mutagenic effect (Ames test) No Noa,e 
hERG IC50 (µM) 10.5 >30 
CYP3A4 IC50 (µM) >25 >100 
aFor racemate (71). bPreclinical batch. cCaco-2 data from reference 54. dMDCK-MDR1 
data; no P-gp mediated efflux. eNot mutagenic in strains TA98 and TA100, either in the 
presence or absence of metabolic activation (S9 fraction). 
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Figure 1. Structures of antitubercular or antileishmanial agents 
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Figure 2. Scaffold hopping to 7-substituted 2-nitroimidazooxazines 
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Figure 3. Comparative in vivo efficacy against L. don in the mouse model: (a) 50 mg/kg, (b) 
25 mg/kg and (c) 6.25 mg/kg 
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Figure 4. Effect of lipophilicity on potency against L. inf for 35 racemic 7-H analogues 
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Figure 5. Comparative in vivo efficacy against L. inf in the hamster model (LMPH) 
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Figure 6. Comparison of 6, 34, and 38 in the acute TB infection mouse model 
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Scheme 1a 
 
 a Reagents and conditions: (i) Br(CH2)2CH=CH2 or 15, K2CO3, DMF, 60-73 °C, 4.5-11 h; 
(ii) OsO4, NMO, CH2Cl2, 20 °C, 4 h; (iii) TIPSCl, imidazole, DMF, 20 °C, 2-3 d; (iv) NaH, 
DMF, 0-20 °C, 3.4 h (for 12), or 0-20 °C, 2.5 h then 46 °C, 3 h (for 19); (v) 1% HCl in 95% 
EtOH, 20 or 44 °C, 1.5-3 d; (vi) ArCH2Br or 4-BnOBnCl, NaH, DMF, 0-20 °C, 2.5-7 h; (vii) 
ArB(OH)2, toluene, EtOH, 2 M Na2CO3, Pd(dppf)Cl2 under N2, 86-90 °C, 20-75 min; (viii) 
Ac2O, pyridine, 20 °C, 38 h; (ix) preparative chiral HPLC (see text); (x) K2CO3, aq MeOH, 
20 °C, 4 h. 
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Scheme 2a 
 
a Reagents and conditions: (i) ArOH, DEAD, PPh3, THF, 0-20 °C, 15-51 h; (ii) ArB(OH)2, 
DMF, (toluene, EtOH), 2 M Na2CO3 or 2 M KHCO3, Pd(dppf)Cl2 under N2, 70-91 °C, 1.5-5 
h; (iii) 15, K2CO3, DMF, 73 °C, 14 h; (iv) m-CPBA, Na2HPO4, CH2Cl2, 0-20 °C, 18 h; (v) 
ArOH, K2CO3, MEK, 82-83 °C, 8-10 h; (vi) NaH, DMF, 0-20 °C, 2-2.5 h; (vii) 57 or 97, 
NaH, DMF, 0-20 °C, 2.3-3 h; (viii) bis(pinacolato)diboron, KOAc, DMF, Pd(dppf)Cl2 under 
N2, 84-90 °C, 3.5 h, then 104, 2 M Na2CO3, Pd(dppf)Cl2 under N2, 85-90 °C, 2.5-3.5 h.  
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Scheme 3a 
 
a Reagents and conditions: (i) Br(CH2)2CH=CH2 or 72 or 80, K2CO3, DMF, 70-74 °C, 19-
72 h; (ii) m-CPBA, CH2Cl2, 0-20 °C, 34 h; (iii) 68, K2CO3, MEK, 81-84 °C, 19-42 h; (iv) 
NaH, DMF, 0-20 °C, 2.5-3.5 h; (v) ArB(OH)2, DMF, (toluene, EtOH), 2 M Na2CO3 or 2 M 
KHCO3, Pd(dppf)Cl2 under N2, 70-90 °C, 2-4 h; (vi) 1 M HCl, MeOH, 0-20 °C, 6 h; (vii) 
TsCl, pyridine, -10 to 20 °C, 13-15 h; (viii) DBU, CH2Cl2, 0-20 °C, 8-9 h. 
  
75 
 
Scheme 4a 
 
a Reagents and conditions: (i) 121 or 124 or 127, NaH, DMF, 0-20 °C, 2.5-3 h; (ii) 
ArB(OH)2, DMF, toluene, EtOH, 2 M Na2CO3 or 2 M KHCO3, Pd(dppf)Cl2 under N2, 80-90 
°C, 2.3-3.5 h; (iii) EtOCH2Cl, K2CO3, DMF, 20 °C, 16 h; (iv) 1.25 M HCl in MeOH, 53 °C, 
4 h; (v) 137, K2CO3, MEK, 83 °C, 24 h; (vi) NaH, DMF, 0-20 °C, 3 h.  
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Scheme 5a 
 
a Reagents and conditions: (i) amine (140, 145, 150, or 155), MEK (or DME), 70-85 °C, 
16-84 h; (ii) NaH, DMF, 40-60 °C or 0-20 °C (for 170) or 20-39 °C (for 178), 1.5-5 h; (iii) 
triphosgene, Et3N, THF, 20 °C, 30 min, then 140, THF, 20 °C, 2 h; (iv) 163, NaH, DMF, 70 
°C, 14-28 h; (v) TBSOTf, 2,6-lutidine, CH2Cl2, 0-20 °C, 1-2.5 d; (vi) H2 (60 psi), 10% Pd-C, 
EtOH, EtOAc, 20 °C, 45-51 h; (vii) I2, PPh3, imidazole, CH2Cl2, 20 °C, 17-19 h; (viii) 2-
chloro-4-nitroimidazole, K2CO3, DMF, 63-75 °C, 70-72 h; (ix) TBAF, THF, 20 °C, 5-25 h.  
77 
 
Table of Contents graphic 
 
 
